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Head and neck squamous cell carcinoma (HNSCC) is the sixth-leading cause of cancer 
fatalities worldwide. Furthermore, a societal rise in obesity has coincided with an increased 
prevalence of head and neck cancers, portending potentially deleterious co-morbidities. The work 
outlined in this dissertation identifies novel avenues towards our understanding of how tumors 
mediate immune escape in both lean and obese experimental models, as well as potential 
limitations and considerations in developing effective immunotherapeutics. Proteins of key 
importance towards these efforts are type I interferons (IFN-I), characterized as potent activators 
of anti-tumor immunity. Indeed, this dissertation expands our mechanistic understanding of how 
stimulator of interferon-inducible genes (STING)-mediated IFN-I production and signaling 
proves to be a central mechanism in facilitating anti-tumor T-cell and myeloid cell expansions. 
We find that tumors from obese mouse models display increased tumor burden alongside an 
immunosuppressed tumor microenvironment. Palmitate, a saturated fatty acid and essential 
component of adipose tissue, dysregulates IFN-I production in both cancer and immune cells, 
leading to increased anti-tumor immune responses. Alongside this, the regulatory nucleotide-
binding domain and leucine-rich repeat (NLR) protein NLRC3, which has been previously 
characterized as a negative regulator of IFN-I production in myeloid cells, is identified here as a 
negative regulator of IFN-I production within human and mouse oral cancer cells. NLRC3 
expression is additionally induced in tumors derived from obesity models, indicating potential 
linkages between saturated fatty acids and innate immune sensors. Through assessment of the 
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IFN-I-related metagene MX1, we uncovered that downstream paracrine and autocrine IFN-I 
signaling within oral cancer tumors is subsequently harmful to patient survival and tumor burden, 
by initiating events leading to the expansion of cancer stem cells. Thus, through this work, we 
reveal pleotropic nature of IFN-Is in modulating the tumor microenvironment. Cancer-intrinsic 
IFN-I production promotes pro-inflammatory anti-tumor immune activation, largely dependent 
on myeloid and cancer cell IFN-I production and myeloid IFN-I downstream signaling, while 
downstream cancer-intrinsic IFN-I signaling enacts a remodeling of the tumor microenvironment 
through the expansion of cancer stem cells, supporting cancer immune escape.
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CHAPTER 1 – Introduction 
 
The work conducted within this dissertation describes mechanisms that regulate both 
tumor development and the tumor microenvironment in head and neck squamous cell carcinoma 
(HNSCC). The underlying theme of the outlined experiments pertains to the role of type I 
interferon (IFN-I) proteins in mediating both pro-inflammatory immune cell infiltration into 
tumor sites as well as immune evasion. The following introduction provides context on current 
research strategies and modalities currently being investigated towards enhancing anti-tumor 
immunity. The success of immune checkpoint receptor blockade has brought exciting promises 
for the treatment of HNSCC. While patients who respond to checkpoint inhibitors tend to 
develop a durable response, fewer than 15% of HNSCC patients respond to immune checkpoint 
inhibitors, underscoring the critical need to alleviate cancer resistance to immunotherapy. Central 
genomic events in HNSCC have been found to possess previously unknown roles in suppressing 
immune sensing. Such inhibitory functions impact both the innate and adaptive arms of tumor-
specific immunity. While checkpoint blockade effectively reinvigorates adaptive T-cell 
responses, additional targeting of the oncogenic inhibitors of innate immune sensing likely 
informs a novel and potent strategy for immune priming. Thus, the second chapter outlines such 
a novel mechanism, by which the innate immune sensor NLRC3 negatively regulates the double-
stranded DNA-dependent IFN-I pathway, and markedly suppresses Tc1 and TH1 immune cell 
responses in mouse tumor models.  Additionally, chapter two delineates a mechanism by which 
obesity mediates increased host tumor burden, through the suppression of IFN-I production and 
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signaling by palmitate. Chapter three examines how downstream cancer-intrinsic IFN-I signaling 
is detrimental for patient survival and tumor burden, indicating the pleiotropic nature of IFN-Is 
in cancer immunology. Lastly, chapter four will abridge the importance of the findings outlined 
in chapters two and three and discuss avenues for future investigation. 
 
Introduction to Head and Neck Squamous Cell Carcinoma 
Head and neck cancer is the sixth leading cause of cancer-related death globally, with 
over 500,000 new cases diagnosed each year (1). Head and neck squamous cell carcinoma 
(HNSCC), the major subtype of this disease, is responsible for over 90% of new cases (2).  
Current standard-of-care treatments are often associated with significant morbidity that limits the 
patient quality of life (3, 4). 
Immunotherapy has emerged as a paradigm shift in cancer therapy, with unprecedented 
durability in patient response and substantially improved patient quality of life. Cancer 
immunotherapy approaches rely on the pivotal role of the immune system in recognizing and 
eliminating transformed malignant cells.  
Fitting with the well-established observation that the incidence of squamous cell 
carcinomas is higher in immunocompromised patients (5, 6), the alleviation of cancer-
potentiated immune suppression has shown potential in reducing HNSCC tumor burden and 
improving patient quality of life (7-9). The success of monoclonal antibodies blocking the 
immune checkpoint receptors (ICRs) signaling has transformed the landscape of emerging 
cancer therapeutic pipelines. This line of treatment aims to enhance the function of CD8+ 
cytotoxic T-lymphocytes (CTL), which play a crucial role in recognizing and eliminating tumor 
cells. Two signals are needed to activate CD8+ T-cells: T-cell receptor interaction with the 
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MHC-peptide complex (signal 1) and CD28-mediated co-stimulation (signal 2). To prevent 
excessive immune activation that is often linked to autoimmunity, ICRs are employed to fine 
tune the magnitude of immune activation. The characterization of two pivotal members of the 
ICR family, Programmed cell Death protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated 
protein 4 (CTLA-4), informed the clinical advance in ICR blockade therapy. PD-1 pathway 
dampens signal 1 and CTLA-4 tunes down signal 2 (10). Thus, blocking ICRs can reinvigorate 
the effector function of CTLs.  
Although less than 15% of the patients responded to ICR blockade, the responders 
developed a durable response (7-9). This important observation is similar to results from phase 
III immunotherapy trials for other cancer types (11, 12). In this review, we will discuss recently 
identified pathways that can be further exploited to enhance immune priming for ICR blockade.  
 
Genetic basis for oncogenic suppression of immune sensing of HNSCC 
It is well-established that the efficacy of ICR blockade is dictated, at least in part, by a 
sufficient number of infiltrating CTLs. Somatic mutations give rise to a pool of neoantigens that 
could be potentially perceived by CTLs. Higher mutation load is found to be associated with 
better response to immunotherapy (13). Compared to many cancer subtypes, HNSCCs have a 
high mutational load (14). However, their response rates to ICR blockade remain modest, which 
raises the possibility that other mechanisms also contribute to HNSCC immunogenicity. The 
expansion of tumor-specific CTLs depends on proper tumor recognition and antigen processing 
by the innate immune system, which employs an array of sensors, aka pattern recognition 
receptors, to become the first responders to abnormal cells. The collective effort in the Cancer 
Genome Atlas Consortium (TCGA) revealed cancer-specific molecular circuitry with 
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unprecedented details. Emerging evidence suggests certain genetic and genomic alterations 
specifically interfere with innate and adaptive immune sensing of tumors (Figure 1-1). 
 
Figure 1-1 – Genetic abnormalities in HNSCC contributes to poor tumor immunogenicity 
 
Aberrant signaling resulting from genes controlling processes ranging from self-renewal to 
metabolism can lead to deficits in cancer immunogenicity. The transcription factor SOX2 has 
been recently implicated in negatively regulating IFN-I-mediated anti-tumor immune responses, 
by promoting the autophagosome-mediated degradation of the ER-resident protein STING, 
leading to decreased immune infiltration.  PIK3CA is commonly co-amplified with SOX2 in 
HNSCC, leading to the activation of the mTOR pathway, which reduces CTL infiltration into the 
tumor microenvironment. 
SOX2 dampens type-I interferon-mediated immune sensing of HNSCC 
One such recurrent genetic event, 3q amplification, which occurs in 16% of HNSCC 
patients from the TCGA and contains transcription factor SRY-box 2 (SOX2), has emerged as a 
pivotal oncogenic driving event that promotes the initiation, proliferation, and malignant 
transformation of squamous cell carcinomas (SCCs), in addition to its well-known role in 
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maintaining stemness. SOX2 is amplified in a wide range of SCCs, and its expression in HNSCC 
is correlated with decreased patient survival (15), higher incidences of nodal metastasis, and a 
higher cancer stage at the time of initial diagnosis (16). Among HNSCCs, SOX2 has been 
demonstrated to promote disease pathogenesis by driving tumor initiation and self-renewal of 
cancer stem cell populations (17-20).   
In addition to these critical functions, recent work has uncovered a surprising role for 
SOX2 in the potentiation of cancer immune escape in HNSCCs. In particular, SOX2 emerged 
from an RNA-Seq-based screen selecting for cancer cell-intrinsic genes associated with the 
development of resistance to immune killing. Interestingly, in an immunocompetent mouse 
model of HNSCC, Sox2-overexpressing tumors displayed diminished CD8+ CTL infiltration and 
enhanced tumor growth, suggesting that SOX2 dampens antitumor immunity in vivo. Further 
investigation revealed that these effects are mediated by SOX2-mediated suppression of the 
stimulator of interferon genes (STING)-dependent type-I interferon (IFN-I) signaling pathway. 
STING senses cytoplasmic DNA, which is frequently present in cancer cells that are sustaining 
DNA damage due to unstable genome and treatments, and triggers the production of IFN-I to 
promote antigen-presenting cell maturation. The centricity of the STING-IFN-I signaling axis 
has been corroborated in pre-clinical models of several cancer types including HNSCC (16, 21-
23). Effective delivery of STING agonists expands tumor-specific CTLs and synergizes with 
ICR blockade (16, 23). Not surprisingly, suppression of this pathway has emerged as a common 
strategy used by cancer cells to potentiate immune escape, which is evidenced by frequent loss of 
STING expression in the tumor cells (24, 25). As a previously unknown mechanism, SOX2 
promotes autophagy-dependent turnover of STING, suppressing IFN-I activation. In agreement, 
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SOX2-high HNSCCs exhibit increased regulatory T-cells and decreased M1-like macrophages 
infiltration, a phenotype that is commonly seen with a deficiency in STING signaling (16).  
 
Activation of the PI3K pathway promotes adaptive resistance to ICR blockade  
 Frequent SOX2 amplification is a defining feature of a major subset of HNSCC. Notably, 
SOX2 and PIK3CA genes are both located at the 3q26.3 locus and frequently co-amplified in 
HNSCCs. Aberrant phosphatidylinositol 3-kinase (PI3K) pathway activation, particularly via 
mutation or amplification of the gene PIK3CA is central for the transformation of HNSCC. Data 
from TCGA HNSCC cohort indicate that the majority of patients with this tumor type display 
genetic alterations in one or more PI3K pathway members and that over half of these PI3K-
altered patients harbor mutations or copy number alterations in PIK3CA (26, 27).  HNSCC with 
multiple concurrent PI3K mutations are all advanced, suggesting its critical role in tumor 
development (28). PIK3CA activates mTOR signaling and promotes HNSCC growth and 
resistance to EGFR-targeted therapy (29). In addition to its well-characterized role in promoting 
cancer cell proliferation, emerging evidence suggests that targeting PI3K represents a promising 
strategy to improve immunotherapy. Such improvement is likely achieved by the pleiotropic 
effects of PI3K inhibition on both cancer cells and CTLs.  
Innate immune priming expands CTLs, and ICR blockade helps to alleviate CTL 
exhaustion. However, sustained CTL activation entails rapid genome replication, active 
migration to come in proximity to target tumor cells, production of large amounts of cytokines de 
novo, and establishment of immunologic synapses. All of these processes are metabolically 
demanding and require bioenergetics support. Indeed, extracellular glucose is a key nutrient 
source to maintain CTL effector function, and deprivation of extracellular glucose leads to rapid 
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CTL exhaustion (30-34). However, a hallmark of cancer is its prioritization of the aerobic 
glycolysis pathway over oxidative phosphorylation, a phenomenon coined as the Warburg effect 
(35). PI3K promotes glucose uptake and enhances glycolysis via the mTOR-AKT pathway (36). 
Tumor cells with activating mutations or amplifications of the PIK3CA gene may directly 
compete with CTLs in the microenvironment for the limited glucose supply. Thus, inhibiting the 
PI3K pathway is a promising approach to reprogram cancer metabolism in the tumor 
microenvironment to favor sustained immune effector activation. 
 In addition to promoting the Warburg effect in tumor cells, PI3K pathway also directly 
enhances CTL exhaustion in HNSCCs. A potential adaptive resistance mechanism to ICR 
blockade is the compensatory upregulation of other ICR members. Utilizing clinical HNSCC 
specimens, a recent study demonstrated that the ICRs PD-1 and T-cell Ig and mucin domain-3 
protein (TIM-3) are co-expressed by the most exhausted and dysfunctional CTLs. Interestingly, 
PD-1 blockade-treated HNSCC patients exhibit upregulated TIM-3 expression by CTLs, and 
such upregulation is dependent on the activation of the PI3K/AKT pathway (37). Thus, targeting 
the PI3K pathway can also directly prevent compensatory induction of additional ICR signaling 
to maintain CTL activation. 
 
Other oncogenic pathways that modulate host immune responses to HNSCC 
 The amplification of the 3q26.3 locus is not the only event that engages the host-tumor 
interface. For example, active β-catenin signaling was initially characterized to be associated 
with a T-cell-poor tumor microenvironment among 266 patients with metastatic cutaneous 
melanomas. Interestingly, SOX2 was also discovered in this patient cohort as a significant factor 
driving T-cell exclusion (38), in agreement with another unbiased whole transcriptome screen 
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that utilizes HNSCC cells (16). Activated WNT/β-catenin drives melanoma resistance to 
checkpoint blockade (38). In a more recent pan-cancer type bioinformatics analysis of the TCGA 
database, mutations of β-catenin signaling components were also more frequently found in non-
T-cell-inflamed specimens (39). 
 The human papillomavirus (HPV) is another oncogenic factor that emerges as a regulator 
of the immune microenvironment. The distinction of HPV+ HNSCC was initially made 
prominent through a retrospective analysis of the prognostic potential of HPV status. The HPV+ 
HNSCC subset shows a significantly lower hazard ratio for death (40). However, the impact of 
HPV on the tumor immune environment and response to immunotherapy is more complex with 
interesting findings from randomized phase III trials. Two of such trials are CheckMate 141 and 
KEYNOTE-040. Based on the initial report of CheckMate 141 and a two-year follow-up of the 
same cohort, the response rates between HPV- and HPV+ groups were similar with almost 
identical hazard ratios (7, 8, 41). Similarly, the results from KEYNOTE-040 suggests that the 
hazard ratio for pembrolizumab vs. standard-of-care was 0.77 with a 95% CI of 0.61-0.97. 
Interestingly, the hazard ratio for pembrolizumab vs. standard-of-care was 0.97 with a 95% CI of 
0.63-1.49 in the HPV+ (p16+) group (9), suggesting that pembrolizumab did not significantly 
reduce hazard risk of death in this group. In-depth examinations of the T-cell receptor repertoire 
within HNSCC reveal either similar or worse T-cell clonal expansion in the HPV+ subset (42, 
43). Thus, despite the more favorable clinical response to standard-of-care, HPV+ tumors may 
present not yet fully understood challenges that smolder treatment-induced immune activation.  
 
 9 
Strategies to improve innate immune priming to sensitize cold HNSCC 
One of the key goals of immune priming is to polarize the immunologically “cold” 
tumor, which lacks sufficient T-cell infiltration and is resistant to checkpoint protein blockade, 
towards an immunological milieu which is deemed “hot” or highly T-cell inflamed (44) (Figure 
1-2). The innate immune system constitutes the first line of defense against cancer. The innate 
immune sensors capture conserved molecular patterns that are associated with tissue damage to 
alert the adaptive arm of immunity. As discussed above, cytoplasmic DNA is a recently 
identified damage-associated molecular pattern that is commonly present in cancer cells. 
However, DNA-induced STING-mediated IFN-I activation is often suppressed in a subset of 
HNSCC by oncogenes. Thus, strategies to bypass oncogenic inhibition of innate immune sensors 





Figure 1-2 – Strategies to improve innate immune priming to sensitize cold tumors 
 
A multipronged approach is needed to most effectively prime the tumor microenvironment for 
ICR blockade. The goal of immune priming is to release frequent oncogenic inhibitors of the 
innate and adaptive immune signaling, to expand the pool of tumor-specific CTLs, and to 
metabolically support the activation of antigen-presenting cells and effectors. Some immune-
priming approaches have shown promises in HNSCC immunotherapy, including but are not 
limited to cancer vaccines, radiotherapy, DNA-damage-inducing chemotherapy, and metabolic 
reprograming agents. 
 
Utilize IFN-I agonists as vaccine adjuvant 
 From an unbiased transcriptome-wide screen, the IFN-I signaling-centered defense 
response emerges as the most critical pathway regulating HNSCC cells sensitivity to immune 
effector-mediated cytotoxicity (16). In addition, IFN-I agonists potently create a TH1-skewed 
cytokine milieu to activate macrophages and dendritic cells (45, 46). Indeed, IFN-I-inducing 
agents show remarkable efficacy in various tumor models. A prototypic experimental vaccine 
adjuvant is CpG, which induces IFN-I in a Tlr9-dependent fashion. CpG-based vaccines can 
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significantly expand tumor-specific CD8+ CTLs and improve the tumor response to ICR 
blockade (47). However, the TLR9 expression profile in humans is drastically different from that 
in mice. Tlr9 is broadly expressed by the myeloid compartment in mice, which underpins the 
success of CpG-based formulations in polarizing the antigen-presenting cells towards a 
productive anti-tumor immune response. However, TLR9 expression is largely absent in the 
human myeloid compartment except for plasmacytoid dendritic cells (48, 49). Thus, novel IFN-
I-inducing adjuvants that are evolutionarily conserved in tissue distribution are explored to 
improve cancer immunotherapy.  
One of these adjuvants is STING agonist cGAMP. As cGAMP is a highly polar 
molecule, several independent groups have reported different delivery system to improve its 
pharmacokinetic properties. One such model uses a peptide hydrogel-based system, known as 
“STINGel,” for delivering STING agonist intratumorally (23). This platform achieves extended 
release of drug, due to the semi-solidified state the drug conforms when injected into the tumor. 
This technology increases the survival rate of the mice bearing an ICR blockade-resistant 
HNSCC model (23).  
Emerging nanoparticle-based approaches for immunotherapy have shown remarkable 
efficacy in pre-clinical HNSCC models. Nanoparticle classes are comprised of versatile carriers 
for an array of treatments, and as a whole, can deliver high-density antigens to the tumor 
microenvironment (50). Nanoparticles can be also designed to accumulate in the lymph nodes, 
increasing APC uptake of antigen and improving cross-priming (51). One of such examples is a 
system coined as the nanosatellite. The nanosatellite vaccine significantly enhances the efficacy 
of cGAMP, accumulates in the draining lymph nodes, improves APC maturation, expands 
tumor-specific CTL and improves HNSCC response to ICR blockade. Interestingly, the 
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nanoparticle-based STING agonist delivery system shows better efficacy than using Montanide, 
one of the strongest clinical-grade adjuvants(16). Overall, new technologies and targeted 
therapies to bypass oncogenic suppression of innate immune sensors likely substantially improve 
HNSCC response to ICR inhibitors. 
 
Radiation can prime HNSCC for ICR blockade 
 Radiation therapy (RT) is a critical component of the standard-of-care for patients with 
HNSCC.  Due to the more favorable response to RT among patients with HPV+ HNSCC, 
randomized phase III trials have assessed potential options for treatment de-escalation. Recently, 
two of such studies confirmed that RT plus cisplatin remains the standard-of-care (52, 53). 
Conventionally, these responses to RT are found to be dependent on the production of reactive 
oxygen species, resulting in DNA damage and ER stress, and on the induction of apoptosis. 
Interestingly, recent evidence suggests that the efficacy of RT depends on an intact immune 
response as RT loses its efficacy in immunocompromised hosts (21). As a mechanism, following 
RT-induced DNA damage, the resulting DNA fragments in the cytoplasm likely engage the 
STING pathway to prime the tumors for ICR blockade therapy (21, 54). MHC class-I genes are 
downstream targets of IFN-I signaling. It is known that HNSCC exhibits reduced expression of 
MHC class-I molecules, as a mechanism of immune escape. RT can directly increase MHC 
class-I expression (55-57), possibly through the STING-IFN-I axis.  Improved responses to RT 
combined with PD-L1 blockade have been reported using an orthotopic mouse model of HNSCC 
(55).  The authors of these studies showed that effects were dependent on infiltration of CD8+ T-
cells (55, 58).  Targeting additional ICRs such as Tim-3 can further enhance responses (59-61).   
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Despite these promising preclinical data, the most effective combination of RT with 
immunotherapy remains incompletely understood. Clinically, several factors require further 
investigation and may necessitate patient- or subgroup-specific treatment protocols.  These 
factors include the patient population of interest (early stage/curative versus 
recurrent/metastatic), the timing of RT treatment (before or after surgery as well as neoadjuvant, 
concurrent, or adjuvant with immunotherapy), and the specific dosing and fractionation of 
radiation treatment.  HPV positivity may be also an important biomarker for patient 
stratification.  These considerations are being evaluated in a variety of ongoing clinical trials, 
which were recently reviewed elsewhere (56). 
 
DNA damage-inducing agents reduces tumor-potentiated immunosuppression 
Cytotoxic chemotherapies, in particular DNA damaging agents such as cisplatin and 5-
fluorouracil (5-FU), are commonly used in the treatment of HNSCC.  Platinum-based 
chemotherapies bind to DNA and result in the formation of inter- and intra-strand cross-links, 
while 5-FU is a pyrimidine analogue that inhibits thymidylate synthase.  Although through 
different mechanisms, both inhibit DNA replication.  These agents are administered widely, 
given alone or with radiation, surgery or other cytotoxic agents or targeted therapies. 
 
Although DNA damage agents have conventionally been considered immunosuppressive, 
recent evidence suggests that they may also have immunostimulatory effects (56, 62).  HMGB1 
and calreticulin are released following the administration of platinum therapies and activate 
TLR4-mediated tumor immune responses, although these effects may be specific to oxaliplatin 
(63, 64). Cisplatin has shown both immunosuppressive and immunostimulatory roles, depending 
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on dosing. A recent study found that sublethal cisplatin helps to increase the expression levels of 
antigen-presenting machinery and immunogenic killing. Higher doses of cisplatin dampen the 
production of IFN-γ by T-cells (65). Due to the different pharmacokinetics of cisplatin between 
murine models and human, additional studies would be informative to determine the optimal 
dosing of cisplatin when designing a combination trial. Several DNA damage agents have been 
shown to decrease the number and/or function of myeloid-derived suppressor cells (MDSCs) 
(66-69); effects on MDSCs, however, may not be specific to this drug class (70-72) and can in 
other cases occur in the opposite direction (73).  Platinum-based therapies can also activate 
cytotoxic T-cells via STAT6-dependent reductions in PD-L2 expression (74) and/or increased 
permeability to granzyme B (75).  Further supporting the potential role of DNA damaging agents 
in improving responses to immunotherapy, inhibition of ATR, a critical component of the DNA 
damage response, can promote T-cell killing by preventing the PD-1/PD-L1 interaction (76).  An 
inhibitor of ATR can prevent RT-induced PD-L1-upregulation and decrease Tregs in the 
implantable tumors (77). Finally, in vivo data recently published by Tran et al. demonstrated the 
benefit of combining low-dose cisplatin with PD-L1 inhibitors in an immunogenic model of 
HNSCC (65).  Ongoing clinical trials, such as NCT02358031, will further inform rational design 
of combinatorial strategies to expand the pool of responders to ICR blockade.   
 
Metabolic reprogramming enhances immune effector function 
Aberrant metabolic rewiring is a hallmark of cancer. Emerging evidence suggests that 
cancer-associated metabolites have a potent impact on intra-tumoral immune cell function. For 
example, high levels of lactate, generated as a byproduct of increased glycolysis in cancer cells, 
increases the acidity of the TME. This increased acidity subsequently polarizes macrophages 
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towards an immunosuppressive M2-like phenotype and impairs the activity of CTLs to emit 
cytokines such as IFN-γ (78, 79). In addition, the depletion of amino acids from the TME leads 
to nutrient restriction, aiding the dysregulated activity of CTLs (80). Recently, findings in 
melanoma indicate that pH neutralization of the TME both increases immune cell infiltration and 
improves the efficacy of ICR inhibitors anti-PD1 and anti-CTLA-4 (81).  
Increased glycolysis is driven by a number of genetic alterations in HNSCC, including 
the PI3K-mTOR pathway. The activation of mTOR activity has been shown to promote the 
expression of glucose transporter proteins such as GLUT1 and GLUT2, thus boosting glycolytic 
flux (82). Interestingly, in addition to the well-characterized function in inhibiting tumor 
proliferation, mTOR inhibitors have been found to exhibit previously unknown effect on 
immune activation. Inhibition of mTOR pathway may reduce MDSCs and increase the ratio of 
M1-/M2-like macrophages in HNSCC models (83).  A combination of mTOR inhibitor with ICR 
blockade results in improved survival in an immunogenic HNSCC model (84).   
 
Challenges and Future Directions 
We have discussed a number of promising immune-priming approaches to sensitize cold 
tumors to ICR blockade. Due to the profound efficacy of inhibition of innate immune sensors on 
the anti-tumor immune response, there are likely multiple oncogenic inhibitors of the IFN-I 
pathway in addition to the published literature. Additional identification of these critical 
checkpoints for host innate immune response not only helps identify cold cancers, but also sheds 
light to the design of novel adjuvants to maximally prime tumors for immune response.  
While therapeutic vaccines are a highly promising approach to synergize with ICR 
blockade, many previous cancer vaccine trials have failed to yield promising results. There are 
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several important considerations when designing the next-generation cancer vaccines. (i) The 
choice of vaccine antigens is critical. Tumor-associated antigens are also expressed by normal 
tissue, albeit at lower levels. These antigens may be less immunogenic than tumor-specific 
antigens, such as HPV oncoproteins and somatic mutation-elicited neoantigens, due to the 
naturally developed central tolerance. (ii) Novel and robust vaccine adjuvants are crucial to 
improve efficacy. The extended characterization of the oncogenic inhibitors of innate immune 
sensors may reveal previously unknown classes of adjuvants to prime the immune system. (iii) 
The development of next-generation delivery may overcome many common challenges with an 
emulsion-based vaccine, such as rapid components degradation and inefficient uptake by the 
antigen-presenting cells. Thus, developing additional nanoparticle and controlled release systems 
will likely bring transformative changes to immune-priming strategies. 
Novel rational combinations need to be tested in a spectrum of immunocompetent animal 
models. HNSCC is a molecularly heterogenous disease, and thus, no single model can capture 
the full spectrum of key genetic alterations. New murine HNSCC cell lines that capture distinct 
genomic features of human disease would be highly desirable to develop the most robust 
immunotherapeutic. Fully appreciating the critical importance of implantable models, these cell 
lines are already transformed and able to surpass host-intrinsic immunosurveillance. Thus, they 
cannot recapitulate the transformation process as pre-malignant cells adopt key genomic events 
to suppress innate and adaptive immune response and establish an immune privileged niche. 
New genetically defined transgenic models can further complement the implantable models to 
rigorously test novel combinatorial immunotherapies. 
Overall, exciting breakthroughs have been made by elucidating the mutation landscape in 
HNSCC and characterizing the efficacy of ICR blockade among this group of patients (27). Built 
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upon the advances in HNSCC ICR blockade immunotherapy, novel priming strategies are central 





CHAPTER 2 – The Innate Immune Sensor NLRC3 Influences Obesity-Mediated IFN-I 
Suppression and Cancer Immune Escape 
 
Abstract 
Worldwide, the incidence rates of head and neck squamous cell carcinoma (HNSCC) continue to 
rise each year. Alongside this, a societal epidemic of obesity has presented unique challenges to 
our understanding of how adiposity affects tumor progression. In this study, we analyzed the 
effects of obesity on modulating HNSCC tumors and anti-tumor immune cell infiltrates. We 
found that administration of murine HNSCC tumors into obese mice led to increased tumor 
burden and a non-immunogenic cellular profile when compared to normal weight mice.  Tumors 
from obese mice treated with the STING-activating cyclic dinucleotide (CDN) cGAMP 
exhibited reduced tumor burden, but with a less efficacious rate than normal weight mice. 
Subsequent analyses revealed that palmitate, a saturated fatty acid and major component of 
adipose tissue, suppresses cancer-intrinsic type I interferon (IFN-I) responses, while oleate, an 
unsaturated fatty acid, does not. To then understand what was driving palmitate-mediated 
suppression of IFN-I production and signaling, we assessed a panel of innate immune sensors 
and identified the gene NLRC3, which is upregulated in tumors from obese mice and HNSCC 
cells treated with palmitate. To understand the effects of NLRC3 on cancer-intrinsic 
immunogenic responses, we used NLRC3-deficient human and mouse cell lines to uncover its 
role as a negative regulator of the cancer-intrinsic IFN-I response. In vivo, NLRC3-deficient 
tumors grew much smaller than control and exhibited greater effector-cell genetic correlates and 
anti-tumor immune cell infiltrates. The efficacy of NLRC3-deficiency in mediating an improved 
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anti-tumor response is directly dependent on both host adaptive immunity and host IFN-I 
signaling. Overall, this work highlights a novel regulatory mechanism by which adiposity 
induces an innate immune sensor to drive cancer-intrinsic immunosuppression. 
 
Introduction 
Current investigations towards improving treatments for head and neck squamous cell carcinoma 
(HNSCC) aim to enhance the efficacy of cytolytic and associated anti-tumor immune subsets in 
combating tumorigenesis (85, 86). It is presently understood that activation of the double-
stranded DNA type I interferon (IFN-I) signaling pathway, via engagement of STING, is critical 
for mediating immunogenic responses to cancer (87, 88). Specifically, this pathway is known to 
amplify dendritic cell (DC) maturation and cross-presentation (89), support the production of 
pro-inflammatory cytokines (90) and enhance effector CD8+ T-cell compartments (21, 91). As 
such, first-line treatments for patients with advanced HNSCC, such as radiation therapy, activate 
multiple priming pathways that sensitize the immunosuppressed tumor microenvironment to 
become activated (56). However, these treatment regimens are associated with significant co-
morbidities, such as dysphagia and osteoradionecrosis (92, 93).  Additionally, in a phase I 
clinical trial examining the efficacy of a cyclic dinucleotide STING agonist towards the 
treatment of solid tumors, the disease control rate yield was 20% (94), indicating potential 
discrepancies in our understanding of other immunoinhibitory mechanisms promoting tumor 
expansion.  Alongside this, the dysregulation of inflammatory pathway activation, a hallmark of 
obesity, is hypothesized to adversely affect cancer patient outcomes (95). In particular, a 
prospective study assessing the association between body mass and head and neck cancer (HNC) 
incidence determined that the risk of developing HNCs directly correlates with increased 
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abdominal weight (96), suggesting potential interplay between fatty acids and cell-intrinsic 
machinery which promotes cancer immune escape. 
In this chapter, we aim to address mechanisms by which obesity promotes tumor growth and 
suppresses anti-tumor immune responses. We found that saturated fatty acids, major components 
of adipose tissue, downregulate IFN-I signaling through the promotion of NLRC3, an innate 
immune sensing protein responsible for inhibiting cancer-intrinsic IFN-I production. We 
additionally uncover how NLRC3-mediated tumor inhibitory mechanisms are dependent on both 
adaptive immunity and host IFN-I signaling. 
 
Materials and Methods 
Animals  
Eight-week-old C57BL/6 (strain 000664), Ifnar1–/– (strain 32045-JAX), and Rag1–/– (strain 
002216) mice were purchased from The Jackson Laboratory and housed under specific 
pathogen–free conditions in a temperature- and light-controlled environment. To establish obese 
mouse model, C57BL/6 mice were fed either a normal diet (5L0D, LabDiet, 24.6% protein, 
11.4% fat, 57.3% carbohydrate, 4.09 kcal/g) or a 60% kcal% fat diet (D12492, Research Diets, 
20% protein, 60% fat, 20% carbohydrate, 5.21 kcal/g) for twelve weeks before tumor 
implantation. As sex is not a known prognosticator for HNSCC, both sexes were used. 
Syngeneic HNSCC models were established by inoculation of 1 million empty vector control, 
shNLRC3, or wild-type MOC2-E6/E7 cells subcutaneously in the right flank.  To test drug 
efficacy, 3 weekly doses of mock (PBS, 100 μL) or 2’3’-cGAM(PS)2 (Rp/Sp) [50 μg/100 μL; 
catalog no. tlrl-nacga2srs, InvivoGen] were administered intratumorally. Beginning on day 7 
after tumor implantation, tumors were measured using a digital Vernier caliper every 2–3 days, 
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and tumor volume was calculated according to the formula 1/2 (length × width2). All mice were 
euthanized at the indicated time points. After euthanasia, tumors, TILs, and spleens of the mice 
were resected for subsequent analysis. 
 
Cell culture  
The HNSCC cell line PCI-13 was acquired from the University of Pittsburgh. FaDu was 
purchased from ATCC (HTB-43). Human cell lines were authenticated and maintained in 
DMEM (10-013-CV, Corning) supplemented with 10% FBS (Gibco, Life Technologies), 100 
U/mL penicillin (Gibco), and 100 mg/mL streptomycin (Gibco). The MOC2-E6/E7 cell line was 
cultured in 60% IMDM (SH30228.01, HyClone) with 30% F12 nutrient mix (11764-054, 
Gibco), 5% FBS, 4 μg/mL puromycin, 5 μg/mL insulin, 40 ng/mL hydrocortisone, 5 ng/mL 
EGF, 100 U/mL penicillin, and 100 mg/mL streptomycin. NLRC3–knockout cells were 
established by transduction of HNSCC cells (PCI-13, FaDu) with an NLRC3-targeting 
CRISPR/Cas9 lentivirus. Control cells were transduced with empty vector virus. EV-MOC2-
E6/E7 and shNlrc3-MOC2-E6/E7 cell lines were transduced with empty vector control (EV) or 
shNlrc3-expressing lentiviruses (MilliporeSigma) followed by puromycin selection 
(concentration 120 μg/mL). Puromycin was purchased from InvivoGen (ant-pr-1). qPCR on 







Bone marrow-derived macrophage isolation and differentiation 
 
Bone marrow-derived macrophages (BMDMs) were isolated from adult female mice to assess 
type I interferon responses in immune compartments. In brief, mice were anesthetized, after 
which the two posterior femurs, tibias, and fibulas were resected from mice, sterilized with 70% 
ethanol, and placed within the biosafety cabinet. Bone ends were subsequently cut, and bone 
marrow was flushed out using a 27 G ½ in needle (305109, BD) and BMDM differentiation 
media (RPMI media with L-glutamine containing 20% heat-inactivated FBS, 30% L-929 cell 
supernatant, and 1% penicillin / streptomycin). Bone marrow in differentiation media was then 
filtered using 70µm cell strainer and split evenly into 6 tissue treated dishes containing 10ml per 
plate. On day three post-plating, an additional 10ml differentiation media was added to aid 
cellular growth. On day six post-plating, media was removed, and dishes were washed once with 
1X PBS. Cells were then gently removed from the plate in 5ml 1X PBS using a 25cm cell 
scraper, spun down, and counted. Cells were plated for experimental use in 6-well tissue culture 
plates, 0.5 x 106 cells / well in 2ml BMDM culture media (RPMI media with L-glutamine 
containing 20% heat-inactivated FBS and 1% penicillin / streptomycin). 
 
Preparation of fatty acid conjugates 
Preparation of saturated and unsaturated fatty acids in vitro was performed as previously 
described (97, 98). In brief, to prepare the BSA solution, 10% (w/v) fatty acid-free bovine 
albumin (A9418-5G, MilliporeSigma) was gradually added to ultrapure water at 52°C with 
gentle agitation until the BSA was fully dissolved. To prepare palmitate, 2.6% (w/v) of palmitic 
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acid (P0500, Sigma-Aldrich) was added to 0.1M NaOH and heated to 70°C until fully dissolved, 
yielding a concentration of 100 mM. Likewise, sodium oleate was added to ultrapure water at 
55°C to yield a concentration of 100 mM. To conjugate fatty acids to BSA, the 100 mM stocks 
of palmitate and sodium oleate were added to 10% BSA at a ratio of 1:9 and heated at 55°C for 
10 minutes. After conjugation, both the 10% (w/v) BSA solution and fatty acid-BSA solutions 
were filter sterilized using a 0.45µm PES filter (SLHVR33RS, Fisher Scientific), aliquoted and 
stored at −20◦C. Before use, solutions were warmed to 37◦C. For final use, 200µM of both fatty 
acid-BSA conjugates were used. 
Plasmids, antibodies, inhibitors, and antibiotics 
The pcDNA3.1–human STING–HA and pcDNA3.1–murine STING–HA expression plasmids 
were provided by Glen N. Barber at the University of Miami (Miami, Florida, USA). The 
lentiCRISPRv2 plasmids were acquired from Addgene (catalog 98290). The single-guide RNA 
(sgRNA) targeting NLRC3 sequence was 5′-CCGGGTCTCCATCACTATCG-3′. The 
pcDNA3.1 empty vector (EV) was previously described (99). Poly(dA:dT) (tlrl-patn-1) and 
cGAMP (tlrl-nacga23-1) were purchased from InvivoGen. Murine pLKO.1-shIFNAR1-puro, 
pLKO.1-shNLRC3-puro and pLKO.1–empty vector–puro lentiviral constructs were obtained 
from MilliporeSigma (Clone ID# TRCN0000067279, Clone ID# TRCN0000249396 and catalog 
number SHC001V, respectively). Lentiviral packaging vectors were provided by Jenny P.Y. 
Ting at the University of North Carolina at Chapel Hill (Chapel Hill, North Carolina, USA).  All 
cells were maintained in a humidified incubator at 37°C with 5% CO2.  Primary antibodies used 
for immunoblotting were as follows: β-actin (ab49900, Abcam), phospho-TBK1 (Ser172) 
(5483S, Cell Signaling Technology), TBK1 (3504S, Cell Signaling Technology), phospho-
STING (Ser365) (D84FW, Cell Signaling), STING (13647S, Cell Signaling Technology) 
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phospho-IRF-3 (Ser396) (4D4G, Cell Signaling), and IRF-3 (D83B9, Cell Signaling). The 
secondary antibodies used for immunoblotting were goat anti-rabbit IgG–HRP (ab97051, 
Abcam) and goat anti-mouse IgG–HRP (ab97023, Abcam).  
Gene expression qPCR and ELISA 
Total RNA was extracted using QIAshredder and the RNeasy Plus Mini Kit (catalog 79654 and 
74134, respectively; Qiagen). RNA concentration was measured using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific). RNA was reverse-transcribed into cDNA using 
High-Capacity cDNA Reverse Transcription Kit and RNAse inhibitor (4368814 and N8080119, 
Applied Biosystems). The primers were synthesized by Integrated DNA Technologies. Gene 
primers utilized were as follows:  ISG15 F 5′-CTGAGAGGCAGCGAACTCAT, R 5′-
AGCATCTTCACCGTCAGGTC; ISG54 F 5′- ACGGTATGCTTGGAACGATTG, R 5′-
AACCCAGAGTGTGGCTGATG; MX1 F 5′-CAATCAGCCTGCTGACATTG-3′, R 5′-
TGTCTCCTGCCTCTGGATG-3′; NLRC3 F 5′-GTGCCGACCGACTCATCTG', R 5′-
GTCCTGCACTCATCCAAGC; HPRT1 F 5′- ATGCTGAGGATTTGGAAAGG, R 5′-
CAGAGGGCTACAATGTGATGG; Ifnb1 F 5′-CCAGCTCCAAGAAAGGACGA, R 5′-
CGCCCTGTAGGTGAGGTTGAT; pan-Ifna F 5′-CCTGAGAGAGAAACACAGCC, R 5′-
TCTGCTCTGACCACYTCCCAG; Cxcl9 F 5′-GAGCAGTGTGGAGTTCGAGG, R 5′-
TCCGGATCTAGGCAGGTTTG; Cxcl10 F 5′-AATGAGGGCCATAGGGAAGC, R 
AGCCATCCACTGGGTAAAGG; Mx1 F 5′-TCTGAGGAGAGCCAGACGAT', R 5′-
ACTCTGGTCCCCAATGACAG; Tnf F 5′-ATGAGAAGTTCCCAAATGGC-3′, R 5′-
CTCCACTTGGTGGTTTGCTA-3′; Ifng F 5′-CGGCACAGTCATTGAAAGCCTA, R 5′-
GTTGCTGATGGCCTGATTGTC; Glut1 F 5’-AGCCCTGCTACAGTGTAT, R 5’-
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AGGTCTCGGGTCACATC; Hk1 F 5’-AGGGCGCATTACTCCAGAG, R 5’-
CCCTGTGGGTGTCTTGTGTG; Pdk1 F 5’-GGACTTCGGGTCAGTGAATGC, R 5’-
TCCTGAGAAGATTGTCGGGGA; Hif1a F 5’-ACCTTCATCGGAAACTCCAAAG, R 5’-
ACTGTTAGGCTCAGGTGAACT; Nlrp3 F 5’-CACGAGTCCTGGTGACTTTGT, R 5’-
GGGGCTTAGGTCCACACAGAAA; Nlrp12 F 5’-CCTCTTTGAGCCAGACGAAG, R 5’-
GCCCAGTCCAACATCACTTT; Nlrp3 F 5’-TGCTCTTCACTGCTATCAAGCCCT, R 5’-
ACAAGCCTTTGCTCCAGACCCTAT; Nod2 F 5’-CACACATGGCCTTTGGTTTCCAGT, R 
5’-AAAGAGCTGCAGTTGAGGGAGGAA; Nlrx1 F 5’-CCTGGATGAGGTGAACTTGG, R 
5’-CTGCTGTCAGTGGGTTGTTG; Nlrc3 F 5’-CACCGTGGGTCACTTGTATCGCACC, R 5'-
AAACGGTGCGATACAAGTGACCCA-3'; Hprt1 F 5′-GATTAGCGATGATGAACCAGGTT, 
R 5′-CCTCCCATCTCCTTCATCACA. Murine IFN-β in the supernatant was quantified using a 
LumiKine™ Xpress mIFN-β 2.0 kit (luex-mifnbv2, Invivogen). 
Immunoblotting assays 
Whole-cell lysates in each well were harvested on ice in RIPA buffer (50 mM Tris-HCl pH 8.0, 
1% Triton X-100, 0.05% SDS, 0.25% deoxycholate, 150 mM NaCl, and 50 mM NaF) 
supplemented with a protease inhibitor cocktail (11836170001, Roche) and Halt Phosphatase 
Inhibitor Cocktail (78420, Thermo Fisher Scientific). The dilutions for the primary antibodies 
were as follows: β-actin, 1:100,000; and 1:1000 for other antibodies. All antibodies were diluted 
in 5% skim milk. After lysates were harvested on ice in RIPA buffer, the samples were rotated at 
4°C for 30 minutes and centrifuged at 13,000 g for 10 minutes at 4°C.  
AlamarBlue assay  
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Empty vector control or shNlrc3 MOC2-E6/E7 cells were seeded at a density of 500 cells per 
well in 96-well microplates with a flat black bottom (3904, Corning). Every 24 hours from day 1 
to day 4, corresponding wells were supplemented with 10% alamarBlue (DAL1025, Invitrogen), 
and the plate was subsequently incubated at 37°C for 4 hours. The fluorescence intensity 
(excitation 560, emission 590 nm) of these wells was measured using a Biotek plate reader and 
Gen5 program (version 2.09), and 5 replicates per group were examined simultaneously. 
Flow cytometry.  
Immune cells from tumors and spleens were purified. Tumors were excised from mice, weighed, 
and minced into pieces, followed by tissue dissociation and passage through a 70-μm cell strainer 
to obtain a single-cell suspension. Spleens were processed by mechanical dissociation, followed 
by lysis of red blood cells (A10492-01, Gibco). Ficoll-Paque PLUS (17-1440-03, GE Healthcare 
Life Sciences) was added to the bottom of each tube containing single-cell suspensions in 
RPMI1640, followed by density-gradient centrifugation to purify immune cells. In general, 
approximately 1 x 106 tumor-infiltrating lymphocytes were extracted from tumors post-Ficoll 
purification.  Cells were subsequently stained for multi-fluorophore flow cytometric analysis 
with the following antibodies: anti-CD45 (clone 30-F11, BioLegend), anti-CD3 (clone 17A2, 
Biolegend), anti-TCR beta (clone H57-597, Biolegend), anti-TCR gamma/delta (clone GL3, 
Biolegend), anti-CD4 (clone RM4-5, BioLegend), anti-CD8 (clone 53-6.7, BioLegend), anti-IFN 
gamma (clone XMG1.2, Biolegend), and anti-PD-1 (clone 29F.1A12, Biolegend). Cells were 
also stained for viability using Zombie Aqua (423101, BioLegend) diluted 1:1000 in PBS at 4°C 
for 30 minutes. Acquisition and compensation were conducted on a Beckman Coulter CytoFLEX 
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flow cytometer. Approximately 0.5 x 105 tumor-infiltrating lymphocytes were acquired per 
experiment. FlowJo version 10 software was used for data analysis. 
Single-cell immune profiling 
Whole tumor lysate was treated with ACK Lysing Buffer (A1049201, ThermoFisher), then 
processed through an EasySep Dead Cell Removal (Annexin V) Kit (17899, STEMCELL 
Technologies). The cell suspension was submitted in 1× PBS + 0.04% BSA for 10× Genomics 
3’-single-cell processing and RNA-Seq at a depth of at least 30,000 reads per cell. We utilized 
the following criteria to select high-quality transcriptomes: (i) the qualified cells must have 
unique feature counts between 200 and 7,500; (ii) the mitochondrial reads must be fewer than 
10%; (iii) the transcriptomes must have unique molecular identifiers counts over 500. We 
integrated 5,154 high-quality transcriptomes for downstream analyses. We utilized the 
sctransform tool to remove the library size effect and the mutual nearest neighbors algorithm to 
remove the batch effect for final integration. We selected the top 2,025 genes with the highest 
cell-to-cell variation as well as features to stabilize the immune population structure. 
Statistics 
Statistical analysis between 2 independent groups was made using unpaired, 2-tailed Student’s t-
tests. Comparisons between more than 2 groups were made using 2-way ANOVA with Šidák’s 
multiple-comparisons post hoc analysis. Tumor burden between groups was compared using 
both the generalized estimating equation model, unless otherwise specified. Statistical 
significance is indicated in all figures according to the following scale: *p < 0.05; **p< 0.01; 
***p< 0.001; and ****p< 0.0001. All graphs are presented as the mean ± SEM. 
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Study approval 
All animal procedures were performed in accordance with the protocol approved by the 
Institutional Animal Care and Use Committee at the University of Michigan (PRO00008517). 
The clinical protocol to obtain HNSCC specimens was approved by the University of Michigan 
Institutional Review Board (HUM00042189 and HUM00113038), with informed consent 
obtained from all patients. 
Results 
Obesity mediates an increased tumor burden and non-immunogenic cellular microenvironment 
To understand the effects of obesity on both tumor burden and the associated 
microenvironment, we first established an obese mouse model by feeding four- to six-week-old 
C57BL/6 mice either a normal chow diet (consisting of 11.4% kcal fat content) or a 60% kcal 
high-fat diet for twelve weeks (100), and monitored mouse weights weekly (Figure 2-1 A). After 
twelve weeks, we utilized the MOC2-E6/E7 syngeneic HNSCC tumor model, which is classified 
as a non-immunogenic cell line that responds poorly to checkpoint therapies (16, 101). One 
million MOC2-E6/E7 cells were implanted subcutaneously into the right flank of mice fed either 
normal chow or a high fat diet and monitored for tumor burden starting one week following 
implantation (Figure 2-1 B). We found that mice fed a high fat diet (classified as “obese”) 
displayed a higher tumor burden in relation to mice fed normal chow (Figure 2-1 B). It has been 
previously reported that increased fatty acid synthesis can portend disrupted glucose metabolic 
responses (102). To understand the potential metabolic differences in tumor burden between 
groups, we resected tumors at day 21, homogenized, and performed qPCR analysis on 
intermediates of the glycolysis pathway. We found the tumors from obese mice displayed higher 
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levels of Glut1, Hk1, Pdk1, and Hif1a, indicating metabolic reprogramming of the cancer cell 
(Figure 2-1 C-F).  
 
Figure 2-1: Obesity mediates an increased tumor burden & altered metabolic profile 
 
(A) Weight curves from C57BL/6 mice fed either normal chow or 60% kcal high fat diet for 15 
weeks. Weight differences between groups were assessed using the generalized estimating 
equation model (**P< 0.01). (B) MOC2-E6/E7 cancer cells were implanted into the right flank 
of mice fed either normal chow or a high fat diet and monitored for tumor burden (n=16 mice per 
condition). Tumor burden between groups was compared using the generalized estimating 
equation model. (C-F) Transcripts of the glycolysis pathway intermediates Glut1, Hk1, Pdk1, 
and Hif1a were quantified from whole excised tumor via qPCR (n=8 normal weight mice; n=6 
obese mice). All comparisons between 2 groups were made using a 2-tailed unpaired t-test (*P < 
0.05 and ****P< 0.0001). 
 
To further assess the effects of obesity on the tumor microenvironment, we purified TILs 
and spleens using Ficoll-Paque gradient and analyzed via flow cytometry. Our gating strategy 
was as follows: Lymphocytes, single cells, Zombie Aqua negative (viability), CD45-positive, 
TCRb-positive, CD4-positive (Figure 2-2 A-F). In our analysis, we found decreased infiltration 
of pro-inflammatory TCRβ+CD4+ IFNγ+ (Figure 2-2 G-H) cells as well as decreased 
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TCRβ+CD4+ PD-1+ T-cells (Figure 2-2 I-J), a population associated with activated IFN-I 
signaling (103). 
Figure 2-2: Obesity mediates an immunosuppressed tumor microenvironment 
(A-F) Gating strategy was as follows: Lymphocytes, single cells, Zombie Aqua negative 
(viability), CD45-positive, TCRb-positive, CD4-positive. (G-J) Frequency of (G-H) CD4+
IFNγ+ and (I-J) CD4+ PD-1+ T-cells assessed from ficoll-purified tumor infiltrating lymphocytes 
from normal weight and obese mice via flow cytometry (n=8 normal weight mice; n=6 obese 
mice).. All comparisons between 2 groups were made using a 2-tailed unpaired t-test (*P < 
0.05). 
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Furthermore, to characterize the complete cancer-associated landscape between groups, 
we performed single-cell RNA sequencing (scRNA-seq) on Ficoll-Paque isolated CD45+ 
immune cells as well as epithelial cell adhesion molecule (EpCAM)-positive cells, to render 
genetic exploration of immune and highly proliferative tumor cells. After filtering, we integrated 
high-quality transcriptomes and identified 20 distinct cell clusters (Figure 2-3 A-D). Of note, we 
found a reduction in signatures from a Sting1+CD40+ M1-like macrophage population (cluster 
6) and increased frequency of M2-like macrophages (cluster 3) in tumors from obese mice. Also 
uncovered were reductions in Ki67-positive and –negative Tbet+ Tcells (clusters 11 and 19) and 






Figure 2-3: scRNA-seq analysis reveals an immunosuppressed tumor microenvironment 
from obese hosts.  
 
(A) Tumors from normal weight and obese mice were harvested at day 21 after implantation. 
TILs were purified and pooled (n=5 mice/condition) and subjected to single-cell RNA-
sequencing expression patterns of immune and tumor cell subsets. After filtering, 5,154 high-
quality transcriptomes were integrated for UMAP analysis. Divergent myeloid, lymphoid, and 
epithelial lineages were defined by the top 2,025 genes with the highest cell-to-cell variation.  
(B) Cluster expression graphic displayed from groups in (A).  (C) Correlations between myeloid 
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and lymphoid subsets and the two experimental groups. (D) Correlations between distinct 
clusters and expression between the two experimental groups. (E-I) Analysis of differential 
cluster expression between two experimental groups. Clusters with differential expression 
patterns were 6 (Sting1+CD40+ M1-like macrophage population), 3 (M2-like macrophages), 11 
and 19 (Ki67-positive and –negative Tbet+ T-cells), and 16 (an expansion of B cells). 
 
Recent evidence has suggested that obese cancer patients may experience worse clinical 
outcomes in response to cyclic dinucleotide (CDN) therapies which activate STING (104). To 
test this theory in vivo, we implanted one-million MOC2/E6-E7 tumors into mice fed normal 
chow or high fat diet (Supp. Figure 2-1 A). On day 7, we treated mice with either Mock PBS or 
50 μg of 2’3’-cGAM(PS)2, a potent STING agonist, intratumorally, and continued once per week 
for three weeks. The administered 2’3’-cGAMP contains a phosphorothioated modification 
which is more stable in vivo than conventional 2'3'-cGAMP (105). At endpoint, we found that 
tumor burden in obese mice was reduced after CDN therapy, but at a less efficacious rate than 
normal weight mice, indicating the influence of fatty acids in suppressing host IFN-I-associated 
anti-tumor immune responses. 
 
Supplemental Figure 2-1: Efficacy of cyclic dinucleotide therapy is reduced in tumor-
bearing obese mice  
 













































(A) Weight curves from C57BL/6 mice fed either normal chow or 60% kcal high fat diet for 14 
weeks. Weight differences between groups were assessed using the generalized estimating 
equation model (****P<0.0001). (B) Mock (PBS, 100 μL) or 2’3’-cGAM(PS)2 (Rp/Sp) [50 
μg/100 μL] was administered intratumorally once per week for three weeks following 
implantation of MOC2-E6/E7 tumor. Comparisons were made at endpoint using an unpaired t-
test, non-parametric comparison (*P < 0.05) 
 
Palmitic acid, but not oleic acid, suppresses STING-mediated IFN-I production and signaling in 
both cancer & immune cells 
To further characterize the role of adiposity in mediating suppression of STING-related 
IFN-I responses within both cancer and immune cell compartments, we utilized the functional 
activity of palmitic acid, a saturated fatty acid and a key component of adipose tissue, which 
comprises significant proportions of depot fat as well as free fatty acids in blood (106, 107). 
Palmitate, an ester of palmitic acid, is used in vitro to model the effects of obesity (98, 108, 109). 
To examine both cancer and immune cell responses to saturated fatty acids, we pretreated both 
MOC2-E6/E7 WT cells and bone marrow-derived macrophages with either mock (10% BSA in 
ultrapure water) or 200µM palmitate-BSA, as previously described (97, 98) for 24 hours. We 
then activated the STING pathway via transfection of either 1µg/mL STING expression plasmid 
in MOC2-E6/E7 WT cells or 1µg/mL 2’3’-cGAMP in bone marrow-derived macrophages for 16 
hours. STING plasmid is transfected into MOC2-E6/E7 due to model cell-intrinsic HPV16-
mediated suppression of endogenous STING (101). We subsequently collected RNA and 
performed qPCR analysis on IFN-I related gene signatures Ifnb1, Cxcl10, and Mx1. We found 
that within both MOC2 cells (Figure 2-4 A-C) and the immune cell compartment (Figure 2-4 D-
F), IFN-I related gene expression was suppressed after treatment with palmitate. We also 
collected supernatant from the transfected cells and found suppression of IFNβ production 
occurred in both cancer (Figure 2-4 G) and immune (Figure 2-4 H) cells. Lastly, we 
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characterized the expression of intermediates of the STING pathway via Western blot, noting 
that palmitate treatment reduces expression of p-TBK1, p-IRF3, and p-STING in both MOC2 
and BMDMs (Figure 2-4 I-J) indicating that saturated fatty acids are a mechanism for 





Figure 2-4: Palmitate suppresses STING-mediated IFN-I production and signaling in both 
cancer & immune cells  
 
(A-C) MOC2-E6/E7 WT cells were pretreated with 200µM palmitate for 24 hours then 
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Cxcl10, and Mx1 was assessed via qPCR. (D-F) BMDMs were pretreated with 200µM palmitate 
for 24 hours then transfected with 1µg/mL 2’3’-cGAMP for 16 hours. Expression of murine 
Ifnb1, Cxcl10, and Mx1 was assessed via qPCR. (G) MOC2-E6/E7 WT cells were pretreated 
with 200µM palmitate for 24 hours then transfected with 1µg/mL STING expression plasmid for 
24 hours. Supernatant was subsequently collected and assessed for presence of IFNβ via ELISA. 
(H) BMDMs were pretreated with 200µM palmitate for 24 hours then transfected with 1µg/mL 
2’3’-cGAMP for 24 hours. Supernatant was subsequently collected and assessed for presence of 
IFNβ via ELISA. All comparisons between 2 groups were made using a 2-tailed unpaired t-test 
(*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). (I) MOC2-E6/E7 WT and (J) BMDMs 
were pretreated with 200µM palmitate for 24 hours then transfected with (I) 1µg/mL STING or 
(J) 1µg/mL 2’3’-cGAMP for 16 hours. Cell lysate was collected and blotted for the presence of 
STING pathway-related proteins p-TBK1, TBK1, p-IFR3, IRF3, p-STING, STING as well as β-
actin control. 
 
We also assessed the role of unsaturated fatty acids in modulating STING-mediated IFN-
I responses. Oleic acid is a dietary fatty acid that is known to counteract the effects of palmitic 
acid (110). As with palmitate, we examined cancer and immune cell IFN-I responses by first 
pretreating both MOC2-E6/E7 WT cells and BMDMs with either mock (10% BSA in ultrapure 
water) or 200µM oleate-BSA for 24 hours, followed by transfection of either 1µg/mL STING 
expression plasmid in MOC2-E6/E7 WT cells or 1µg/mL 2’3’-cGAMP in bone marrow-derived 
macrophages. After qPCR analysis, we found that oleate did not suppress the expression IFN-I 
related gene signatures Ifnb1, Cxcl10, and Mx1 (Supp. Figure 2-2) indicating that unsaturated 
fatty acids do not modulate the IFN-I response in cancer cells. 
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Supplemental Figure 2-2: Oleate does not suppress STING-mediated IFN-I production and 
signaling in either cancer or immune cells  
 
(A-C) MOC2-E6/E7 WT were pretreated with 200µM palmitate for 24 hours then transfected 
with 1µg/mL STING expression plasmid for 16 hours. Expression of murine Ifnb1, Cxcl10, and 
Mx1 was assessed via qPCR. (D-F) BMDMs were pretreated with 200µM palmitate for 24 hours 
then transfected with 1µg/mL 2’3’-cGAMP for 16 hours. Expression of murine Ifnb1, Cxcl10, 
and Mx1 was assessed via qPCR. Comparisons between 2 groups were made using a 2-tailed 
unpaired t-test. 
 
NLRC3 negatively regulates the dsDNA-dependent IFN-I response in human and mouse cancer 
cells 
Innate immune sensing pathways are critically important for regulating STING-mediated IFN-I 
responses in HSNCC (101, 111). To further expand our understanding of potential cooperation 
between innate immune sensors and adiposity, we extracted RNA from homogenized tumors 
from normal weight and obese mice and assessed the presence of various innate immune sensors 
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Nlrc3 as a gene signature upregulated in obese tumors (Figure 2-5 A-E). NLRC3, a nucleotide-
binding, leucine-rich repeat protein, has been previously characterized as a negative regulator of 
IFN-I signaling within macrophages (112), by blocking the interaction of STING with its binding 
partner TANK-binding kinase 1 (TBK1), preventing the phosphorylation of IRF3, a key 
transcription factor for IFN-I production. To further characterize its function in the context of 
HNSCC, we utilized an NLRC3-targeting CRISPR/Cas9 lentivirus to knockout NLRC3 
expression within the Human HNSCC cell lines PCI-13 (Figure 2-5 F) and FaDu (Figure 2-5 L). 
EV- and NLRC3-knockout PCI-13 and FaDu cells were then transfected with either 1µg/mL 
STING expression plasmid or 1µg/mL poly(dA:dT) for 16 hours, and collected for qPCR 
analysis. Through this analysis, we found that NLRC3 loss in both PCI-13 (Figure 2-5 G-K) and 
FaDu (Figure 2-5 M-Q) cells led to increased expression of the STING-mediated IFN-I gene 
signatures ISG15, ISG54, and MX1, defining NLRC3 as a negative regulator of the cancer-
intrinsic IFN-I response in human HNSCC cells. 
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Figure 2-5: NLRC3 negatively regulates the dsDNA-dependent IFN-I response in human 
cancer cells  
 
(A-E) Transcripts of the innate immune sensing regulators Nlrp3, Nlrp12, Nlrx1, Nod2, and 
Nlrc3 were quantified from whole excised tumor via qPCR (n=8 normal weight mice; n=6 obese 
mice). (F) Human HNSCC cell line PCI-13 was transduced with an NLRC3-targeting 
CRISPR/Cas9 lentivirus. Knockout efficiency was quantified via qPCR. (G-K) EV- and NLRC3-
knockout PCI-13 cells were transfected with either (G-H) 1µg/mL STING expression plasmid or 
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assessed via qPCR. (L) Human HNSCC cell line PCI-13 was transduced with an NLRC3-
targeting CRISPR/Cas9 lentivirus. Knockout efficiency was quantified via qPCR. (M-Q) EV- 
and NLRC3-knockout FaDu cells were transfected with either (M-N) 1µg/mL STING expression 
plasmid or (O-Q) 1µg/mL poly(dA:dT) for 16 hours. Expression of human ISG15, ISG54, and 
MX1 was assessed via qPCR. All comparisons between 2 groups were made using a 2-tailed 
unpaired t-test (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). 
 
Alongside these findings, we also examined the effects of NLRC3 loss in the mouse 
HNSCC cell line MOC2-E6/E7. These cells were transduced with an Nlrc3-targeting shRNA 
lentivirus and assessed via qPCR (Figure 2-6 A). An alamarBlue assay determined there were no 
differences in growth rates between cell lines (Figure 2-6 B). To further characterize the 
relationship between innate immune sensors and saturated fatty acids, MOC2-E6/E7 WT cells 
were treated with either mock BSA or 200µM palmitate-BSA and collected for RNA analysis. 
We found the Nlrc3 expression was increased in palmitate-treated cells (Figure 2-6 C).  To 
delineate the effects of Nlrc3 on the murine cancer-intrinsic IFN-I response, EV- and shNlrc3-
MOC2-E6/E7 cells were transfected with either 1µg/mL STING expression plasmid or 1µg/mL 
poly(dA:dT) for 16 hours. Subsequent qPCR analysis revealed increased expression levels of 
mouse Ifnb1, pan-Ifnα, Cxcl9, Cxcl10, and Mx1 from both STING-transfected samples (Figure 2-
6 D-H) as well as samples treated with poly(dA:dT) (Figure 2-6 I-M). We also characterized 
STING pathway intermediates via Western blot, finding that NLRC3 loss mediates increased p-
TBK1 and p-IRF3, confirming the role of NLRC3 as a negative regulator of cancer-intrinsic 
IFN-I in murine cancer cells (Figure 2-6 N-O). 
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Figure 2-6: NLRC3 negatively regulates the dsDNA-dependent IFN-I response in murine 
cancer cells  
 
(A) Mouse HNSCC MOC2-E6/E7 was transduced with an Nlrc3-targeting shRNA lentivirus. 
Knockdown efficiency was quantified via qPCR. (B) The proliferation of EV control and 
shNlrc3 MOC2-E6/E7 cells was assessed via an alamarBlue assay. Each group included 5 
replicate wells. (C) Nlrc3 expression was measured in MOC2-E6/E7 WT cells pretreated with 
200µM palmitate for 24 hours via qPCR. (D-M) EV- and shNlrc3-MOC2-E6/E7 cells were 
transfected with either (D-H) 1µg/mL Sting expression plasmid or (I-M) 1µg/mL poly(dA:dT) 
for 16 hours. Expression of murine Ifnb1, pan-Ifnα, Cxcl9, Cxcl10, and Mx1 was assessed via 
qPCR. All comparisons between 2 groups were made using a 2-tailed unpaired t-test (*P < 0.05; 
***P < 0.001; ****P < 0.0001). (N-O) EV- and shNlrc3-MOC2-E6/E7 cells were transfected 
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with either (N) 1µg/mL Sting expression plasmid or (O) 1µg/mL poly(dA:dT) for 16 hours. Cell 
lysate was collected and blotted for the presence of STING pathway-related proteins p-TBK1, 
TBK1, p-IFR3, IRF3 as well as β-actin control. 
 
Loss of cancer-intrinsic NLRC3 improves anti-tumor immune response 
To understand the context of cancer-intrinsic NLRC3-mediated IFN-I suppression in 
vivo, we implanted one million EV- or shNlrc3-MOC2-E6/E7 cancer cells into the right flank of 
C57BL/6 mice and monitored tumor burden. We found that NLRC3 loss mediated a smaller 
tumor burden (Figure 2-7 A), as well as decreased tumor weights at endpoint (Figure 2-7 B). (B) 
Whole tumor was homogenized and assessed for the presence of TH1/Tc1-related gene 
signatures. The signatures Cxcl9, Cxcl10, Tnf, and Ifng were found to be induced in shNlrc3-
MOC2-E6/E7 cells, indicating increased infiltration of anti-tumor immune cell populations 
(Figure 2-7 C-F).  
 
Figure 2-7: Loss of cancer-intrinsic NLRC3 promotes an anti-tumor immune profile  
 
(A) EV- or shNlrc3-MOC2-E6/E7 cancer cells were implanted into the right flank of C57BL/6 
mice and monitored for tumor burden (n=6 mice with EV-MOC2-E6/E7 tumors; n=5 mice with 
shNlrc3-MOC2-E6/E7 tumors). Tumor burden between groups was compared using the 



















































































































































































resected and weighed before processing. (C-F) Transcripts of TH1/Tc1-related gene signatures 
Cxcl9, Cxcl10, Tnf, and Ifng were quantified from whole excised tumor via qPCR (n=5 mice 
with EV-MOC2-E6/E7 tumors; n=3 mice with shNlrc3-MOC2-E6/E7 tumors). All comparisons 
between 2 groups were made using a 2-tailed unpaired t test All comparisons between 2 groups 
were made using a 2-tailed unpaired t-test (*P < 0.05; ***P < 0.001). 
 
 
We also performed flow cytometry on Ficoll-Paque isolated TILs. Our gating strategy 
was as follows: Lymphocytes, single cells, Zombie Aqua negative (viability), CD45-positive 
(Figure 2-8 A-D). We found increased frequencies of TCRb+ T-cells (Figure 2-8 E-F), TCRγd+ 




Figure 2-8: Loss of cancer-intrinsic NLRC3 improves the anti-tumor immune response  
 
(A-F) Gating strategy was as follows: Lymphocytes, single cells, Zombie Aqua negative 
(viability), CD45-positive. (E-F) Frequency of TCRb+ T-cells assessed from ficoll-purified 
tumor-infiltrating lymphocytes from normal weight and obese mice via flow cytometry (n=5 
mice per condition). Gating strategy was as follows: Lymphocytes, single cells, Zombie Aqua 
negative (viability), CD45-positive. (G-H) Frequency of TCRγd+ T-cells assessed from ficoll-
purified tumor-infiltrating lymphocytes from normal weight and obese mice via flow cytometry 
(n=5 mice per condition). Gating strategy was as follows: Lymphocytes, single cells, Zombie 
Aqua negative (viability), CD45-positive. (I-J) Frequency of CD8+ PD-1low T-cells assessed 
from ficoll-purified tumor-infiltrating lymphocytes from normal weight and obese mice via flow 
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cytometry (n=5 mice per condition). All comparisons between 2 groups were made using a 2-
tailed unpaired t-test (*P < 0.05). 
 
 To better understand the specific context by which NLRC3 loss mediates improved 
tumor immunogenicity, we implanted EV- or shNlrc3-MOC2-E6/E7 cancer cells into the right 
flank of Rag1-/- mice, which lack T and B cells (113)as well as Ifnar1-/- mice that lack host 
downstream signaling. In both models, cancer-intrinsic NLRC3-mediated immune suppression 
was dependent on both adaptive immunity (Supp. Figure 2-3 A) and host IFN-I signaling 
pathways (Supp. Figure 2-3 B). 
 
Supplemental Figure 2-3: Anti-tumor immunity mediated by loss of cancer-intrinsic 
NLRC3 is dependent on both host adaptive immunity and downstream IFN-I signaling. 
 
(A) EV- or shNlrc3-MOC2-E6/E7 cancer cells were implanted into the right flank of mice Rag1-
/- mice and monitored for tumor burden (n=5 mice per condition). Tumor burden between groups 
was compared using the generalized estimating equation model. (B) EV- or shNlrc3-MOC2-
E6/E7 cancer cells were implanted into the right flank of mice Ifnar1-/- mice and monitored for 
tumor burden (n=7 mice per condition). Comparisons between 2 groups were made at endpoint 
using an unpaired t-test, non-parametric comparison. 
 















































The role of STING-mediated IFN-I production and signaling in producing potent anti-
tumor immune responses has been a promising avenue for treatment strategies aiming to enhance 
the immunogenicity of cold tumors. Traditionally, this pathway is induced by the engagement of 
cytosolic double-stranded DNA to cyclic GMP-AMP synthase (cGAS), catalyzing the formation 
of the second messenger molecule cyclic GMP-AMP (cGAMP). Subsequently, cGAMP acts on 
STING, to activate TBK1, resulting in phosphorylation of IRF3 and the transcription of IFN-I 
proteins. Unfortunately, in the clinic, CDNs alone have currently proven to enact limited efficacy 
towards regression of solid tumors (94). However, therapeutic modalities combining CDNs with 
other immune and metabolic targets could provide the necessary regulatory mechanisms needed 
to boost tumor immunogenicity (94). 
In this chapter, we sought to delineate the interplay between saturated fatty acids 
associated with obesity and the tumor microenvironment. Obesity has previously been negatively 
correlated with head and neck patient outcomes, yet the linkages between tumor immune 
regulation and adiposity were unclear. We first sought to define how obesity affected tumor 
burden, by implanting MOC2-E6/E7 tumors into mice fed a high fat diet, a standard model for 
replicating the effects of obesity, as opposed to those fed a normal chow diet. We found that 
obese mice bore larger tumors, and through tumor microenvironment analysis via flow 
cytometry and single-cell RNA sequencing, we uncovered an immunosuppressed tumor 
landscape, including higher M2-like/M1-like ratios and well as reduced T-cell infiltration. From 
this, it was important to understand the mechanism by which this phenotype was enacted. By 
using palmitate, an abundant saturated fatty acid in adipose tissue, we modeled the effects of 
obesity on both cancer cell signaling pathways as well myeloid compartments in vitro. 
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Pretreatment of palmitate on both murine cancer cells and BMDMs led to suppressed IFN-I 
production, as demonstrated by qPCR and ELISA. This suggested that suppressed IFN-I 
signaling is a mode employed by saturated fatty acids to inhibit immune responses in cold 
tumors. To understand why this suppression occurs, we investigated a panel of innate immune 
sensors largely associated with pro-inflammatory pathways, including previously defined IFN-I 
regulators, to determine if fatty acids modulated the expression of such proteins. We found that 
NLRC3 was induced both within tumors from obese mice as well as MOC2-E6/E7 cells treated 
with palmitate. To further analyze cancer-intrinsic NLRC3 on the IFN-I response, we deleted 
NLRC3 expression via CRISPR/Cas9 in the human HPV-negative HNSCC cell lines PCI-13 and 
FaDu and knocked down NLRC3 in MOC2-E6/E7 cells. Following activation of the STING 
pathway within these tumors, we found that lack of NLRC3 mediated enhanced IFN-I production 
and signaling, confirming its importance as a negative regulator of IFN-I responses in cancer 
cells. Additional characterization revealed that loss of NLRC3 in vivo greatly reduced tumor 
burden and increased frequencies of immunogenic infiltrates, indicating that NLRC3 could 
provide a promising target towards enhancing the efficacies of CDNs and other checkpoint 
inhibitors currently approved for treatments. 
From this work, a novel interplay between saturated fatty acids and the activity of innate 
immune sensors has been uncovered, with interesting potential indications. It has been recently 
reported that NLRC3-mediated sequestration of STING is reversed by DNA binding to the 
leucine-rich repeat domain of NLRC3, which increases its ATPase activity and subsequently 
releases the STING/TBK1 complex (114). From this finding, the question emerges of how 
saturated fatty acids may directly or indirectly interact with NLRC3 machinery, and whether 
NLRC3 itself is a potentially targetable protein to enhance anti-tumor immunity. Future work 
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assessing the interplay between free fatty acids and innate immune sensors will hopefully further 










CHAPTER 3 – Cancer-Specific IFNAR1 Downstream Signaling Is Associated With Worse 
Prognosis and Cancer Immune Escape 
 
Abstract 
Type-I interferon (IFN-I) signaling is critical to maintain cancer immunogenicity and is a key 
contributor to the anti-tumor response. However, recent studies have suggested that IFN-I 
signaling may also contribute to more aggressive tumor phenotypes, raising the possibility that 
IFN-I downstream signaling activation in cancer cells and myeloid populations may exert 
dichotomous roles. Here we examined the prognostic potential of cancer cell-specific IFN-I 
receptor downstream signaling in head and neck squamous cell carcinoma (HNSCC) using an 
expanded cohort of 195 patients by measuring protein levels of MX1, a sensitive surrogate marker 
of IFN-I induction. Kaplan-Meier analysis revealed that MX1-high tumors exhibited significantly 
worse overall survival, a finding which was confirmed in univariate and multivariate Cox 
regression models. To understand the mechanism driving this phenomenon, we administered 
mice with control or Ifnar1-deficient HNSCC cells. Notably, mice bearing Ifnar1-deficient 
tumors exhibited reduced overall tumor burden, reduced proportions of cancer stem cells and 
increased CD4+ and CD8+ T-cell infiltration. In particular, we observed immunosuppressive 
CD4+ PD1high and CD8+ Tim3+ tumor infiltrating lymphocytes (TILs) were significantly 
reduced in shIfnar1 tumors, while CD8+ PD-1low TILs important for antitumor immunity were 
significantly increased. Finally, we also completed single cell RNA-sequencing (scRNA-Seq) 
with subsequent immune cell deconvolution to ascertain the extent to which the overall immune 
landscape is altered in Ifnar1-deficient tumors, which confirmed Ifnar1-deficient tumors exhibit 
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expansions in TILs with a concomitant loss of immunosuppressive myeloid cell populations. 
Thus, the beneficial role of IFN-I receptor activation is largely dependent on the myeloid 
compartment and cancer-specific IFN-I receptor engagement is associated with more aggressive 
cancer outcomes and poor immunogenicity. 
 
Introduction 
As immune checkpoint blockade (ICB) is being moved into a first line setting for cancer 
treatment, co-targeting resistance mechanisms have become central to the outcomes of 
immunotherapies. Conceptually, there are two broad resistance mechanisms. The first is tumor 
and myeloid upregulation of the expression of the inhibitory immune checkpoint receptor 
ligands, such as programmed cell death ligand 1 (PD-L1), to dampen the activation of effector T-
cells. The second class of resistance mechanisms is due to the lack of immune priming signals 
with minimal inflammatory infiltration in the tumor stroma. The first class of mechanisms can be 
efficiently targeted by leveraging combinatorial ICBs. However, most tumors show features that 
fall into the second category. The induction of type-I interferon (IFN-I) signaling has been 
shown as a powerful priming approach to enhance antigen-presenting cells maturation and 
effector expansion, which sensitizes hypoimmunogenic cold tumors to ICB in several preclinical 
cancer models (21, 87, 88). 
According to data from the Centers for Disease Control and Prevention, human 
papillomavirus (HPV)+ Head and Neck Squamous Cell Carcinoma (HNSCC) was one of the 
only five cancer types that increased from 1975 to 2009; and the increase is predicted to continue 
until at least the year 2060 (115, 116). Notably, in contrast to the generally more favorable 
response profiles to chemotherapy among patients with HPV+ tumors, the Hazard Ratios for 
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nivolumab were almost identical between the HPV+ and HPV- groups despite the presence of 
viral epitopes (7, 8). Similarly, pembrolizumab ICB resulted in little survival improvement over 
standard-of-care in patients with HPV+ tumors (9). Our recent study found that HPV potently 
suppresses IFN-I priming signals and encourages cancer immune escape (101). In pre-clinical 
models, we and others engineered IFN-I-inducing vaccines targeting the HPV16 E6/E7 epitopes 
and showed that IFN-I is essential to prepare the tumor microenvironment for a better response 
of ICB-mediated tumor-specific cytotoxic T-cell immunity (16, 23, 87). 
Not surprisingly, IFN-I-inducing agents have entered clinical trials, including agonists for a 
central adaptor molecule stimulator of interferon response cGAMP interactor 1 (STING1), which 
was shown pivotal for radiotherapy-mediated benefits and necessary priming for ICB in animal 
studies (21). There are three known human STING1 alleles, which showed different sensitivities 
to its physiological ligand cGAMP. Novel cyclic di-nucleotides have been engineered to activate 
all known STING1 alleles. However, a substantial subset of patients remains resistant to even 
these broadly activating cyclic di-nucleotides (117). In addition, discrepancies are present in 
studies assessing the role of IFN-I in cancer outcomes. For example, genome instability creates 
micronuclei whose rupture activates the STING1-IFN-I pathway. This encourages cancer 
metastasis and genetic suppression of chromosomal instability delays metastasis even in highly 
aneuploid tumor mouse models (118). Higher expression levels of the Bloom Syndrome RecQ-
like Helicase (BLM) and exonuclease 1 (EXO1), which facilitate the generation of STING1-
inducing DNA fragments, are associated with poor prognosis in response to radiotherapy (119).   
Although the activation of the IFN-I pathway is essential for innate immune detection of 
cancer, it is equally important to understand the mechanisms underpinning the discrepancies in 
these different studies. Unlike the type II and type III interferons, whose production are restricted 
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to a small collection of cell types, IFN-I is highly evolutionarily conserved and almost all normal 
cell types express IFN-I induction machinery and its receptor IFNAR1. The activation of a 
spectrum of pattern recognition receptors, including the Toll-like receptors (TLRs), RNA sensors 
such as DExD/H-Box Helicase 58 (DDX58, aka Retinoic Acid-inducible Gene I or RIG-I), 
Interferon Induced with Helicase C Domain 1 (IFIH1, aka Melanoma Differentiation-Associated 
Protein 5 or MDA5), and DNA sensor cyclic GMP-AMP Synthase (cGAS), lead to the 
phosphorylation of IRF3 and NF-kB. Nuclear phospho-IRF3 and phospho-p65 form an 
enhanceosome to drive the generation of IFN-I, which includes 13 subtypes of IFN-a, IFN-β, 
IFN-ω, IFN-ϵ, and IFN-κ. IFN-I functions in an autocrine or paracrine fashion to engage its 
receptor constituted by IFNAR1 and IFNAR2 on the plasma membrane. Upon activation, 
tyrosine kinases Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) are phosphorylated, 
which leads to the phosphorylation of the Signal Transducers and Activators of Transcription 
(STAT)1 and STAT2. Within the IFNAR1 transcriptional program, MX1 is a transgene that is 
specifically induced by IFN-I and used as a sensitive surrogate marker for IFNAR1 signaling.  
Thus, the generation of IFN-I and its downstream signaling upon binding to IFNAR1 are 
two separate events for cancer cells. The secreted IFN-I may function in a paracrine fashion to 
stimulate the myeloid compartment, which drives most of the observed benefits. However, we 
and others have shown that multiple solid tumors including HPV- and HPV+ HNSCC show 
deficiencies in the IFN-I induction pathway to evade innate immune detection. Notably, their 
IFN-I downstream JAK-STAT pathways are often intact, which can be also activated through the 
Epidermal Growth Factor Receptor (EGFR) pathway (120). Although IFNAR1 downstream 
signaling activation in myeloid cells enhances its antigen processing efficiency and cross-
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priming of CD8+ T-cells, the role of IFNAR1 downstream signaling in cancer cells in regulating 
the tumor immune microenvironment remains insufficiently characterized.  
In this study, we performed a cohort analysis of 195 HNSCC patients to assess the 
prognostic significance of IFNAR1 signaling activation in cancer cells and determine whether 
suppression of the IFNAR1 pathway specifically in cancer cells improves intra-tumoral immune 
infiltration.  
 
Materials and Methods 
Clinical samples and tissue microarray.  
Patients with previously untreated HNSCC were recruited by the University of Michigan Head 
and Neck Cancer Specialized Program of Research Excellence (SPORE) between 2008 to 2012 
for a longitudinal study. The patient demographic information and clinical characteristics are 
summarized in Supplementary Table 2. The tumors from 218 patients, with a median follow-up 
of 60 months, were incorporated into a tissue microarray (TMA). For each tumor, 3 
representative 5-μm cores, identified by head and neck pathologist Jonathan McHugh 
(Department of Pathology, University of Michigan, Ann Arbor, MI, USA), were included, each 
of which contained tumor tissue and surrounding stroma to varying degrees. TMAs were stained 
with anti-MX1 antibody (1:600; Cell Signaling Technology, catalog #37849S). The secondary 
antibody was biotinylated goat anti-rabbit antibody (Vectastain ABC HRP Kit, PK-4001, Vector 
Laboratories). Immunohistochemical (IHC) staining intensity was quantitated in tumor tissue for 
each core by selecting a region of interest (ROI) using Aperio ImageScope, followed by 
quantification according to the following formula: Score = (255-Iavg * Positivity), where Iavg was 
the average intensity and positivity was the number of positive cells. IHC scores were averaged 
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from the 3 cores, and those that were missing or had insufficient tumor parenchyma were 
excluded from subsequent analysis. In total, MX1 IHC scores were available for 195 patients. In 
experiments involving multivariate Cox regression modeling to control for CD4+ and CD8+ 
TILs, immunohistochemistry was performed for CD4 and CD8 followed by manual counting of 
intratumoral CD4 and CD8 numbers for each TMA, in triplicate, by trained observers blinded to 
the clinical information. 
 
Statistics 
Univariate Cox linear regression modeling was used to explore the association between MX1 
expression in TMAs and patient clinical variables (e.g. nodal metastasis, stage, etc.). The 
association between MX1 IHC scores and patient survival was conducted using both univariate 
and multivariate Cox regression models as indicated in Table 1. To dichotomize tumors into 
MX1-low and MX1-high groups, a threshold score was estimated by the change point in a Cox 
regression model, generating a change point cutoff score of 41. Statistical significance in 
survival probability between MX1-low and MX1-high TMAs was evaluated by Kaplan-Meier 
survival curves and a log-rank test. As a secondary method, we compared overall survival (OS) 
and recurrence-free time (RFT) in patients exhibiting MX1 scores in the highest quartile (MX1 
score ≥ 31.79) vs. patients with lower scores. Statistical analysis between 2 independent groups 
was made using unpaired, 2-tailed Student’s t tests. Tumor burden between groups was 
compared using the generalized estimating equation model. Statistical significance is indicated in 
all figures according to the following scale: *P < 0.05; **P < 0.01; ***P < 0.001; and ****P< 




Eight-week-old C57BL/6 (strain 000664), were purchased from The Jackson Laboratory and 
housed under specific pathogen–free conditions in a temperature- and light-controlled 
environment. Because sex is not a known prognosticator for HNSCC, both sexes were used 
equally. Syngeneic HNSCC models were established by inoculation of 1 million empty vector 
(EV-MOC2-E6/E7) control or shIfnar1-MOC2-E6/E7 cells subcutaneously in the right flank. 
Beginning on day 7 after tumor implantation, tumors were measured using a digital Vernier 
caliper every 2–3 days, and tumor volume was calculated according to the formula 1/2 (length x 
width2). Tumor weight was measured after animals were sacrificed followed excision. All mice 
were euthanized at the indicated time points followed by tumor, spleen, and/or TIL harvesting 
for subsequent analysis. All animal procedures were performed in accordance with the protocol 




The MOC2-E6/E7 cell line was cultured in 60% IMDM (SH30228.01, HyClone) with 30% F12 
nutrient mix (11764-054, Gibco), 5% FBS, 4 μg/mL puromycin, 5 μg/mL insulin, 40 ng/mL 
hydrocortisone, 5 ng/mL EGF, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were 
maintained in a humidified incubator at 37°C with 5% CO2. The MOC2-E6/E7 cell line was 
originally obtained from Harvard University and validated by immunoblotting for HPV16 E7 
protein in Figure S3 of our previous publication (16). To generate EV-MOC2-E6/E7 and 
shIfnar1-MOC2-E6/E7 cell lines, MOC2-E6/E7 cells were transduced with empty vector control 
(EV) or shIfnar1-expressing lentiviruses followed by puromycin selection. The selecting 
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concentration of puromycin was determined by the establishment of a kill curve, via addition of 
various doses of puromycin into wild-type MOC2 cells. The determined concentration used was 
120 μg/mL puromycin. qPCR on murine Ifnar1 and Isg54 was performed to validate the 
knockdown efficiency. Murine pLKO.1-shIFNAR1-puro and pLKO.1–empty vector–puro 
lentiviral constructs were obtained from Sigma-Aldrich (catalog SHCLNG-NM_010508 and 
SHC001V, respectively). Lentiviral packaging vectors were provided by Jenny P.Y. Ting at the 
University of North Carolina at Chapel Hill (Chapel Hill, North Carolina, USA).  
 
Gene expression qPCR  
Total RNA was extracted using QIAshredder and the RNeasy Plus Mini Kit (catalog 79654 and 
74134, respectively; Qiagen). RNA concentration was measured using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific). RNA was reverse-transcribed into cDNA using 
High-Capacity cDNA Reverse Transcription Kit and RNAse inhibitor (4368814 and N8080119, 
Applied Biosystems). Primers were synthesized by Integrated DNA Technologies and included: 
Isg54 forward 5′-TCTGGTCACCTGGGGAAACTATG-3′, reverse 5′-
TTCTCAATCCTGTAGGGGCTGG-3′; Ifnar1 forward 5′-TCCCCGCAGTATTGATGAGT-3′, 
reverse 5′-CTGGTCTGTGAGCTGTACTT-3′.  
 
AlamarBlue assay  
Empty vector control or shIFNAR1 MOC2-E6/E7 cells were seeded at a density of 500 cells per 
well in 96-well microplates with a flat black bottom (3904, Corning). Every 24 hours from day 1 
to day 4, corresponding wells were supplemented with 10% alamarBlue (DAL1025, Invitrogen), 
and the plate was subsequently incubated at 37°C for 4 hours. The fluorescence intensity 
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(excitation 560, emission 590 nm) of these wells was measured using a Biotek plate reader and 
Gen5 program (version 2.09), and 5 replicates per group were examined simultaneously. 
 
Flow cytometry  
Immune cells from tumors and spleens were purified as we have previously described (16). 
Briefly, tumors were excised from mice and minced into pieces, followed by dissociation by 
passing through a 70-μm cell strainer to obtain a single-cell suspension. Spleens were processed 
by mechanical dissociation, followed by lysis of red blood cells (A10492-01, Gibco). Ficoll-
Paque PLUS (17-1440-03, GE Healthcare Life Sciences) was added to the bottom of each tube 
containing single cell suspensions in RPMI1640, followed by density-gradient centrifugation to 
purify immune cells. Purified immune cells were stained for multi-fluorophore flow cytometric 
analysis with the following antibodies: anti-CD45 (clone 30-F11, BioLegend), anti-CD3 (clone 
17A2, BD Biosciences), anti-CD4 (clone RM4-5, BioLegend), anti-CD8 (clone 53-6.7, 
BioLegend), anti-CD44 (clone IM7, BioLegend), anti-CD366 [Tim3] (clone RMT3-23, 
Biolegend), and anti-PD-1 (clone 29F1A12, Biolegend). Cells were also stained for viability 
using Fixable Viability Dye (FVD) eFluor 780 (65-0865-14, Thermo Fisher Scientific) or 
Zombie Aqua (423101, BioLegend) diluted 1:1000 in PBS at 4°C for 30 minutes. Acquisition 
and compensation were conducted on a Beckman Coulter CytoFLEX flow cytometer. FlowJo 
version 10 software was used for data analysis. 
 
ALDH assay 
This assay was performed using the ALDEFLUOR™ Kit (01700, STEMCELL Technologies). 
In part, empty vector control or shIFNAR1 MOC2-E6/E7 in vitro lines were resuspended into 
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ALDEFLUOR™ Assay Buffer (01701, STEMCELL Technologies) at a working concentration 
of 1x105. Following ALDEFLUOR staining, cells were stained with anti-CD44, and analyzed on 
a Beckman Coulter CytoFLEX flow cytometer. 
 
Single cell RNA-sequencing and immune cell deconvolution 
Whole tumor lysate was treated with ACK Lysing Buffer (A1049201, ThermoFisher), then 
processed through an EasySep Dead Cell Removal (Annexin V) Kit (17899, STEMCELL 
Technologies). Cell suspension was submitted in 1× PBS + 0.04% BSA for 10× Genomics 3’-
single cell processing and RNA-Seq at a depth of at least 30,000 reads per cell. We utilized the 
following criteria to select high-quality transcriptomes: (i) the qualified cells must have a unique 
feature counts between 200 and 7,500; (ii) the mitochondrial reads must be fewer than 10%; (iii) 
the transcriptomes must have unique molecular identifiers counts over 500. We integrated 12,907 
high-quality transcriptomes for downstream analyses. We utilized the sctransform tool to remove 
the library size effect and the mutual nearest neighbors algorithm to remove the batch effect for 
final integration. We selected the top 3,000 genes with the highest cell-to-cell variation as well as 
features to stabilize the immune population structure. The additional features include Cxcr5, 
Cd69, Aim2, Irf5, Irf1, Irf3, Lgals9, Ly6e, Nos2, Il6, Tnf, Isg15, Gsdmd, Cd8a, Cd40, Cd80, 
Cd86, Il10, Tgfb1, Tmem173, Cd274, Cxcl9, Mrc1, Siglec15, Trdc, Cd2, Trac, Cd4, Cd8b1, 
Foxp3, Trbc1, Trbc2, Gzmb, Eomes, Icos, Cd3d, Cd3e, Ifng, Ncr1, Cd19, Cd79a, Cd79b, Itgam, 
Itgax, Batf3, Xcr1, Gata3, Ctla4, Rorc, Il17a, Bcl6, Havcr2, Tnfrsf4, Tigit, Cxcl10, Mx1, Ifnb1, 
Il3ra, Nrp1, Fcer1a, Tbx21, Lag3, Ifnl3, Pdcd1, Cd14, Ifna4, Ly6g, Ly6c1,  and Lyz2. We 




High MX1 protein expression levels in cancer cells are associated with poor prognosis in 
HNSCC patients  
Tissue microarrays (TMAs) were generated utilizing specimens from 195 patients with 
HNSCC. The majority of specimens were collected from patients with advanced stage disease 
(15% stage 3; 65% stage 4) and were relatively representative of the natural distribution across 
disease sites, including larynx (17%), oral cavity (46%), oropharynx (30%), and 
hypopharynx/other (7%). Other parameters evaluated in this patient cohort, summarized in Table 
3-1, included age, gender, adult comorbidity evaluation (ACE) score, HPV status, and history or 




Table 3-1 – Baseline demographic and clinical information corresponding to the TMAs 
analyzed from an expanded cohort of 195 HNSCC patients (mean follow-up of 60 months) 
 
To assess the prognostic value of cancer cell-specific IFNAR1 downstream signaling, we 
analyzed MX1 protein levels by immunohistochemical staining of the TMAs. MX1 exhibited a 
diffuse cytoplasmic staining pattern that was highly variable in density among different tumors. 
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MX1 is also stained in the infiltrating immune cells, as expected. To specifically examine the 
role of cancer-specific IFNAR1 activation, we manually selected tumor parenchyma for 585 
cores, with three cores representing one tumor, prior to quantitation (Figure 3-1a). Cancer-
specific MX1 staining scores were quantitated using Aperio ImageScope, as we previously 
reported (101). These results supported the heterogeneous nature of MX1 distribution, with 
descriptive statistics summarized in Table 3-2. 
 
 
Table 3-2 – Descriptive statistics for MX1 immunohistochemical staining scores obtained by 
Aperio ImageScope quantification of TMAs from 195 HNSCC patients 
 
 
To analyze the association with relevant clinical variables, MX1 scores were considered in their 
continuous form (the raw score) or in a dichotomized form wherein tumors were divided into 
MX1-high and MX1-low groups using the change point threshold in Cox regression modeling, 
generating a change point cutoff score of 41. No significant association was observed between 
MX1 score and disease site or nodal metastasis, although a trend existed between the raw MX1 
score and advanced cancer stage (P = 0.09) (Supplemental Figure 3-1). 
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Figure 3-1 – High MX1 protein levels is a negative prognosticator in head and neck 
squamous cell carcinoma. 
 
MX1 immunohistochemistry in TMAs from HNSCC patients reveals cytoplasmic staining of 
variable intensity across specimens (A) Raw MX1 scores and survival time are indicated for each 
representative TMA. Scale bar: 200 µm. (B) MX1 staining scores were segregated into MX1-low 
or MX1-high groups and the Kaplan-Meier survival curves of each group were compared using a 
log-rank test.  
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Supplemental Figure 3-1 – Association of MX1 immunohistochemical scores with disease 
site, cancer stage, and nodal metastasis 
 
Raw MX1 scores were generated by quantifying MX1 immunohistochemical staining in TMAs 
from 195 HNSCC patients, followed by correlation with primary disease site (a.), cancer stage 
(b.), or status of nodal metastasis (c.). No statistical differences were observed between MX1 and 
any of these variables, although a non-statistically significant positive association was observed 
between MX1 score and increased HNSCC cancer stages (P = 0.09). Univariate Cox linear 
regression modeling was used to analyze the association between MX1 score and each variable.  
 
We next examined the impact of MX1 protein expression on HNSCC patient overall survival 
(OS). The Kaplan-Meier survival curves were compared between MX1-high and MX1-low 
groups using a log-rank test, which revealed that MX1-high staining was significantly correlated 
with worse overall survival (P = 0.02; Figure 3-1b). Utilizing a univariable Cox regression model 
where MX1 is the single predictor of outcome, we found that the MX1-high group was 
correlated with significantly worse overall survival (P = 0.02), but no association was observed 
with recurrence-free survival (RFS; P = 0.28; Table 3-3). We also built a multivariate Cox 
regression model controlling for age, clinical stage, disease site, ACE scores, HPV status, 
smoking, and CD4+ T-cells among tumor infiltrating leukocytes (TILs), and found that MX1-
high staining remained correlated with significantly worse overall survival (P = 0.04; Table 3-3). 
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Notably, using a multivariate Cox regression model that controls for these factors, but instead 
controls for CD8+ T-cells among tumor infiltrating leukocytes (TILs), MX1-high tumors are no 
longer associated with worse prognosis (P = 0.42; Table 3-3), suggesting that high MX1 staining 
in cancer cells negatively predicts patient outcome in a CD8+ T-cell-dependent manner.  
 
Table 3-3 – Association between MX1 score and overall survival or recurrence-free survival 
 
Displayed above is a univariate model or multivariate models controlling for patient age, clinical 
stage, disease site, comorbidities, HPV status, smoking history, and CD4+ (middle) or CD8+ 
TILs (bottom). 
 
 As a secondary method of dividing patients by their MX1 immunohistochemical scores, 
we compared Kaplan-Meier curves for overall survival (OS) and recurrence-free time (RFT) in 
patients exhibiting MX1 scores in the highest quartile (MX1 score ≥ 31.79) vs. patients with 
lower scores. Interestingly, patients exhibiting MX1 scores in the highest quartile tended to 
exhibit worse overall survival (P = 0.186; not shown) and recurrence-free survival (P = 0.049; 
not shown). In a univariate Cox regression model, patients exhibiting MX1 scores in the highest 
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quartile tended to exhibit worse prognosis in terms of OS (P = 0.07209) and RFT (P = 0.05563; 
Table 3-4). This association was generally stronger when controlling for individual clinical 
parameters such as patient age, stage, site, ACE score, smoking status, and CD4+ or CD8+ 
accounts using multivariate Cox regression modeling (Table 3-4).  
 
 
Table 3-4 – Association between MX1 scores in the highest quartile vs. all other patients in 
terms of overall survival or recurrence-free survival 
 
Loss of IFNAR1 downstream signaling in HNSCC cells reduces tumor burden and improves the 
tumor immune microenvironment 
To directly determine the role of cancer-specific IFNAR1 downstream signaling in tumor 
immunogenicity, we utilized an established MOC2-E6/E7 syngeneic HNSCC model (16), which 
does not produce IFN-I upon transfection with STING1 agonists (101). We produced a 
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derivative model in which the Ifnar1 receptor is knocked down (MOC2-E6/E7-shIfnar1) leading 
to loss of cancer cell-intrinsic IFNAR1 signaling (Figure 3-2a-b). Defective downstream IFN-I 
signaling had no effect on cell proliferation in vitro (Figure 3-2c). Interestingly, when we 
implanted empty vector control (MOC2-E6/E7-EV) and Ifnar1-deficient tumor cells into 
C57BL/6 hosts, we observed a significant reduction in tumor growth in the Ifnar1-deficient 
tumor group (Figure 3-2d-e).  
 
 
Figure 3-2 – Loss of IFN-I signaling in HNSCC cells reduces tumor burden. 
 
(A) qPCR was performed to quantitate the transcript levels of Ifnar1 and (B) the downstream 
IFN-I target gene Isg54 in EV control and shIfnar1 MOC2-E6/E7 cells. (C) The proliferation of 
EV control and shIfnar1 MOC2-E6/E7 cells was measured via an alamarBlue assay. Each group 
included 5 replicate wells. (D-E) One million EV control or IFNAR1-deficient MOC2-E6/E7 
cells were implanted subcutaneously in the right flank of C57BL/6 hosts. (D) Tumor 
measurements were performed every 2–4 days and (E) tumor weight was measured followed 
harvesting at day 36. All Comparisons between 2 groups were made using a 2-tailed 
unpaired t test (**P < 0.01, ****P < 0.0001). 
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When we examined the cancer cell compartment in vitro, we noticed that Ifnar1 
deficiency reduced the fraction of cells showing features of cancer stem cells (Figure 3-3a-b), 
which have been demonstrated to be more resistant to immune killing (121). We separated the 
TILs through a Ficoll-Paque gradient and found an enhancement in both CD4+ and CD8+ T-cell 
infiltration in Ifnar1-deficient tumors (Figure 3-3c-f), suggestive of the elicitation of a T-cell-
inflamed microenvironment in a highly aggressive cold tumor model. 
  
 




(A-B) To assess presence of cancer stem cells, EV control and shIFNAR1 MOC2-E6/E7 cells 
were treated using the ALDEFLUOR Assay Kit and analyzed via flow cytometry for aldehyde 
dehydrogenase-high. Gating strategy was as follows: MOC2 cells, single cells, CD44-high. (C-
F) Tumors were harvested 36 days following implantation, and tumor infiltrating lymphocytes 
(TILs) were separated using a Ficoll-Paque gradient. (C-D) The proportion of CD3+ CD4+ TILs 
were assessed by flow cytometry. Gating strategy was as follows: Lymphocytes, single cells, 
Zombie Aqua negative (viability), CD45-positive. (E-F) The proportion of CD3+ CD8+ TILs 
were assessed by flow cytometry. Gating strategy was as follows: Lymphocytes, single cells, 
Zombie Aqua negative (viability), CD45-positive. All Comparisons between 2 groups were 
made using a 2-tailed unpaired t test (*P < 0.05). 
To more completely characterize the phenotype of CD4+ and CD8+ TILs, we again 
separated TILs from control and Ifnar1-deficient tumors. Notably, while no changes were 
observed in immune subsets in the spleen, we observed a significant reduction in 
immunosuppressive CD4+/PD1high and CD8+/Tim3+ TILs in Ifnar1-deficient tumors (Figure 3-
4a-f), as well as an increase in the fraction of CD8+/PD1low TILs required for antitumor 




Figure 3-4 – Loss of IFN-I signaling in cancer cells promotes a more inflamed tumor 
microenvironment. 
 
(A-C) Tumors or spleens were harvested 36 days following tumor implantation, and 
lymphocytes were isolated using a Ficoll-Paque gradient. The proportion of CD4+ PD1high TILs 
or splenic T cells were assessed by flow cytometry. Gating strategy was as follows: 
Lymphocytes, single cells, Zombie Aqua negative (viability), CD45-positive, CD3 positive.  (D-
F) The proportion of CD8+ Tim3+ TILs or splenic T cells were assessed by flow cytometry. 
Gating strategy was as follows: Lymphocytes, single cells, Zombie Aqua negative (viability), 
CD45-positive, CD3 positive.  (G-I) The proportion of CD8+ PD1low TILs or splenic T cells 
were assessed by flow cytometry. Gating strategy was as follows: Lymphocytes, single cells, 





Cancer-specific IFN-I downstream signaling impacts the global immune landscape 
Collectively, our flow cytometry analyses of TILs suggest that mice bearing Ifnar1-
deficient tumors exhibit a shift towards a more immunologically “hot” tumor microenvironment. 
To comprehensively characterize the impact of tumor-intrinsic IFN-I signaling on the tumor 
immune microenvironment, we performed single-cell RNA-sequencing (scRNA-seq) to render 
the intratumoral immune landscape. We performed Ficoll-Paque purification, followed by 
CD45+ FACS sorting, to enrich intra-tumoral leukocytes. After filtering, we integrated 12,907 
high-quality transcriptomes and identified 20 cell clusters (Figure 3-5a), which showed distinct 
immune lineage segregation and smooth functional transition. The majority of the intratumoral 
leukocytes consisted of the myeloid cells, including myeloid-derived suppressor cells (MDSCs, 
clusters 1, 2, 5, 7, 8, 9, and 12), M2-like macrophages (cluster 13), and conventional dendritic 
cells type 1 (cDC1, cluster 20). The CD4+ T-cells were separated to regulatory T-cells (Treg, 
cluster 15) and a stem-like cluster with high expression levels of Tcf7 (cluster 3). The effector 
populations included Tbet+CD8+ T-cells (cluster 6), Tcf7+CD8+ T-cells (cluster 18), natural killer 
(NK) cells (cluster 17), and gd T-cells (cluster 16). We also identified Cxcr5+ B-cells (clusters 4, 
10, and 11) and a minute population of basophils (cluster 19) (Figure 3-5a). Global intratumoral 
immune microenvironment remodeling was noted when tumor cells were deficient in 
downstream IFN-I signaling (Figure 3-5b-c). Inhibition of cancer-specific Ifnar1 signaling 
transduction expanded the frequencies of CD8+ T-cells by 5.4 folds, Tcf7+CD4+ T-cells by 7.3 
folds, and γδ T-cells by 3.6 folds. There was an about 50% reduction in MDSCs. Also observed 
was a 7.6-fold expansion of Cxcr5+ B-cells in the Ifnar1-deficient tumors (Figure 3-5b-c).  
Thus, using clinical specimens as well as parallel flow cytometry and single-cell analysis, 
we found that activation of downstream IFN-I signaling in cancer cells not only led to lymphoid 
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contraction within the tumors but also resulted in dysfunctional CD8+ T-cells profiles. To 
delineate the impact of cancer-intrinsic IFN-I activation upon the differentiation of CD8+ T-cells, 
we separated the CD8+ subsets (clusters 6 and 18) and performed Potential of Heat-diffusion for 
Affinity-based Transition Embedding (PHATE) analysis, which revealed the functional 
development pathways of CD8+ T-cells. We found that the CD8+ T-cells in empty vector control 
and Ifnar1-deficient tumors assumed divergent functional commitments. MOC2 has been 
established as a hypoimmunogenic HNSCC model that is refractory to ICBs (122, 123). In 
agreement, we found that the CD8+ T-cells in control tumors largely committed to a terminal 
exhaustion phenotype with high expression levels of Pd-1 and Tim-3. These cells were low on 
activation markers such as Cd28 and Cd69 as well as stemness markers Tcf7 and Slamf6. In 
contrast, increased frequency of CD8+ T-cells in Ifnar1-deficient tumors expressed high levels of 
Cxcr3, which is rapidly induced upon activation of Th1 effectors (124). Notably, most of these 
CD8+ T-cells in Ifnar1-deficient tumors preserved stemness features, which are critical in 
maintaining cancer immunogenicity (125, 126). Glutaminolysis has been shown to be activated 
in Th1 cells to support their effector function (127-129). Interestingly, we found that the 
terminally exhausted CD8+ T-cells in control tumors largely lost the expression of a glutamine 
transporter Slc38a2. However, Slc38a2 was highly expressed in CD8+ T-cells that also expressed 




Figure 3-5 – Analysis of the tumor immune landscape by single cell RNA-sequencing with 
immune cell deconvolution. 
 
 74 
(A-C) MOC2-E6/E7-EV control and MOC2-E6/E7-shIfnar1 tumors were harvested at day 36 
after implantation. TILs were purified and pooled from six mice per group and subjected to 
single-cell RNA-sequencing. (A) After filtering, 12,907 high-quality transcriptomes were 
integrated for UMAP analysis. Divergent myeloid and lymphoid lineages were defined by top 
3,000 genes with the highest cell-to-cell variation and enforced features of 69 immune cell 
marker genes. (B) UMAP analyses demonstrating the tumor immune landscape in EV control 
(green) and Ifnar1-deficient (red) tumors are shown. (C) Comparison of the relative proportion 
of cell types identified in EV control and Ifnar1-deficient tumors. Ifnar1-deficient tumors 
exhibited a marked decrease in the proportion of several cell types (red arrows), which was 
particularly pronounced among myeloid-derived suppressor cells (MDSCs, clusters 1, 2, 5, 7, 8, 
9, and 12). In Ifnar1-deficient tumors, increased enrichment was observed in the proportion of 
Tcf7+CD4+ TILs (cluster 3), CD8+ T-cells (clusters 6 and 18), γδ T-cells (cluster 16), as well as 
CXCR5+ B-cells (clusters 4, 10, and 11), as indicated by blue arrows. (D) PHATE analyses were 
performed to reveal the divergent differentiation trajectories of the CD8+ T-cells (clusters 6 and 
18 from Fig. 5a) in empty vector control (black) and Ifnar1-deficient tumors (yellow). The 
expression patterns of functional markers across the CD8+ T-cell landscape were highlighted in 
the rest of the panels, with red showing the highest expression levels and black showing the 
lowest expression levels. 
 
Discussion 
Much progress has been made towards understanding cancer resistance to ICB. A 
preexisting tumor antigen-specific T-cell pool is required for optimal response to 
immunotherapy. STING-mediated IFN-I activation underpins the success of multiple innate 
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immune priming strategies that aim to enrich the tumor-specific T-cell pool. Irradiation, 
inhibition of DNA damage repair, and direct stimulation with cyclic dinucleotides are utilized to 
trigger DNA-induced STING1 activation. However, the efficacy of this broad class of innate 
immune priming treatments is challenged by unknown mechanisms that dampen tumor 
sensitivity to STING1 stimulation. The main focus on the immune remodeling effect of STING1 
agonists had been on the M1-like repolarization of the myeloid cells. This study aims to 
understand whether cancer-specific IFN-I downstream signaling contributes to 
immunosuppression. We first assessed whether cancer intrinsic IFNAR1 signaling is clinically 
significant for patients with HNSCC. Utilizing univariate and multivariate Cox regression 
models, we found that high MX1 protein levels in cancer cells were associated with worse 
overall survival. MX1 is a sensitive surrogate marker for IFNAR1 downstream signaling 
activation, suggesting that sustained IFNAR1 engagement was an unfavorable prognosticator in 
HNSCC. Notably, the association between cancer-specific MX1 expression and worse outcomes 
is dependent on the number of intra-tumoral CD8+ T-cells.  
The current IFN-I agonists were administered to globally activate IFNAR1 signaling in both 
immune cells and other cell types, including cancer cells. The beneficial effect of STING1-IFN-I 
activation is dependent on myeloid reprograming (21, 130). Activation of IFNAR1 signaling not 
only enhances antigen processing, antigen presentation, MHC molecule upregulation, but also 
improves trafficking and recruitment of innate and adaptive immune cells to the otherwise T-
cell-deficient tumor stroma. However, IFNAR1 activation in cancer cells promotes cancer 
stemness and potentiates a T-cell exclusion local niche. IFN-I stimulation not only makes cancer 
cells assume stemness features to develop resistance to immune killing but reprograms the global 
tumor immune microenvironment. We performed parallel flow cytometry and single-cell RNA-
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Seq to reveal the divergent myeloid and lymphoid remodeling imposed by cancer-specific IFN-I 
signaling disruption. We found that Ifnar1-deficient tumors harbors reduced MDSCs and 
expanded effectors including CD8+ T-cells, non-Treg CD4+ T-cells, and gd T-cells.  Notably, 
blocking cancer-specific IFN-I signaling not only expands CD8+ T-cell pool but remodels its 
differentiation trajectory. We utilized a well-established cold cancer model and indeed found that 
majority of the intratumoral CD8+ T-cells have committed to terminal exhaustion with double 
expression of Pd-1 and Tim-3. However, Ifnar1-deficient tumors expands Tcf7+ stem-like 
effector T-cells, which preserves high proliferation potential and responsiveness to ICB. 
Mechanistically, cancer stem cells in HNSCC are a small yet highly tumorigenic population 
which selectively express PD-L1 and dampen autologous CD8+ T-cell activation (121). Thus, 
cancer-intrinsic IFNAR1 signaling activation likely initiates a transcriptional program that is 
overlapping with the cancer stemness program to dampen the anti-tumor effect of STING1 




CHAPTER 4 – Conclusions and Future Directions 
 
Summary 
Head and neck squamous cell carcinomas (HNSCCs) are defined as immunologically 
cold (16), which presents unique challenges in the development of novel therapeutics towards 
improving immune responses (131). Alongside this, a phase 3 clinical trial of the checkpoint 
inhibitor nivolumab, an anti-PD-1 monoclonal antibody, yielded only a 13.3% response rate in 
HNSCC patients (7). Thus, the goal of the research outlined within this dissertation was to 
further delineate both activating and inhibitory mechanisms which influence tumor development 
and immune cell evasion. To answer such questions, we approached the field through the 
examination of type I interferon (IFN-I) regulation, which enacts broad anti-tumor functional 
activity, by activating effector and myeloid immune cell populations (21, 89-91). Though 
previous research has examined the therapeutic benefits of myeloid cell IFN-I production (21, 
130), the effects of cancer-intrinsic IFN-I production and downstream tumor-specific IFNAR1 
engagement had yet to be assessed. In chapter 2, we examined how cancer-intrinsic IFN-I 
production is suppressed in obese hosts, leading to increased tumor burden and a highly 
immunosuppressed tumor microenvironment.  We further identified the gene NLRC3 as 
upregulated in obese tumors, and as a negative regulator of the cancer-intrinsic IFN-I response. 
In addition, the efficacy of NLRC3-deficiency in mediating an improved anti-tumor immune 
response was shown to be dependent on both host adaptive immunity and host IFN-I signaling. 
In chapter 3, we investigated the role of cancer-intrinsic IFN-I downstream signaling towards 
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modulating the tumor microenvironment. We first discovered that MX1, a “metagene” associated 
with downstream IFNAR1 engagement (46) was correlated with worse HNSCC patient survival. 
We also found that cancer-intrinsic IFNAR1-deficiency led to reduced overall tumor burden, 
reduced proportions of cancer stem cells, and reduced immunosuppressive tumor-infiltrating 
lymphocytes (TILs) subsets in hosts. Altogether, the work outlined in this document has 
uncovered that the therapeutic benefits of IFN-Is in mediating cancer immune escape are largely 
dependent on myeloid and cancer cell IFN-I production and myeloid IFN-I downstream 
signaling, and that paracrine and autocrine signaling effects of IFNAR1 activation on cancer 
cells are deleterious for host anti-tumor immune cell responses and patient outcomes (Figure 4-
1). 
 
Figure 4-1 – Schematic of differential outcomes between cancer-intrinsic IFN-I production 













The work outlined in this dissertation has uncovered the differential regulation of tumor 
progression that occurs by the STING-mediated type I interferon pathway. We uncover that IFN-
I production and signaling from the host, as well as is IFN-I production from the cancer cell is 
beneficial for the development of anti-tumor immunity, and this process is suppressed by the 
presence of saturated fatty acids, which induces the IFN-I regulator NLRC3. However, IFN-I 
signaling from the cancer cell promotes tumor immune escape by expanding cancer stem cells, 
proving deleterious for patient outcomes. 
 
Objectives, Major Findings, and Implications from Chapter 2 
The inflammatory processes associated with obesity and associated metabolic disorders 
have previously been linked to driving angiogenesis and expedited tumor development, through 
a variety of immunosuppressive factors, such as HIF-1a and TGF-b, which buttress cellular 
growth (132). In concordance with this work, innate immune regulators have additionally been 
implicated in interacting with reactive oxygen species induced by free fatty acid synthesis, 
leading to disordered inflammation (133). However, until now, we have not fully understood the 
mechanisms by which adiposity mediates tumor immune suppression. In chapter 2, we sought to 
first to determine how obesity modulates head and neck squamous cell carcinoma (HNSCC) 
progression and the associated microenvironment in vivo, and then to further explore the effects 
of saturated fatty acids on regulating cancer and immune cell-associated type I interferon (IFN-I) 
production. 
As mentioned previously, obesity has been correlated with worse head and neck cancer 
patient tumor growth (94); however, body mass cannot alone indicate patient outcomes (134), 
and mechanistic studies underlying these correlations were not clear. To assess the effects of 
obesity on host HNSCC burden, we utilized the previously characterized MOC2-E6/E7 tumor 
model, which is syngeneic to C57BL/6 mice (16). C57BL/6 mice were fed either a normal chow 
diet or a high fat diet for twelve weeks, then implanted with MOC2-E6/E7 cells. Obese mice 
displayed a larger tumor burden than normal weight mice, and through tumor microenvironment 
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analysis, we uncovered an immunosuppressed landscape that included suppressed T-cell 
expansions and increased M2-like macrophage populations. This work suggests that effector cell 
cytokine and chemokine signaling is altered by components of adipose tissue. We also found that 
obesity modulated glycolytic processes within tumor cells.  
To find the fatty acid compartment which could be promoting aggressive tumor growth in 
obese hosts, we used both palmitate, an abundant saturated fatty acid in adipose tissue, as well as 
oleate, an unsaturated fatty acid, to model to effects of obesity within cell culture. Pretreatment 
of palmitate on both murine cancer cells and BMDMs led to suppressed type I interferon (IFN-I) 
production, whereas pretreatment with oleate did not produce this effect. Alongside this, we 
hypothesized that obese patients, who potentially bear a range of metabolic defects, would be 
less responsive to cyclic dinucleotide (CDN) therapy. We thus treated tumor-bearing normal 
weight and obese mice with 2’3’-cGAMP for three weeks and found that the effects of CDN 
therapy were reduced in relation to obesity. 
To understand why saturated fatty acids caused this effect, we investigated a panel of 
innate immune sensors associated with IFN-I signaling pathways by qPCR within obese tumors, 
including NLRX1 (101) and NLRP3 (135). In this analysis, we found that NLRC3, a known 
regulator of the myeloid IFN-I response (112), was upregulated in tumors from obese mice. This 
novel finding indicates that saturated fatty acids directly interact with innate immune sensing 
pathway machinery within both cancer and immune cells to influence inflammatory processes. 
To characterize NLRC3-mediated effects on the cancer-intrinsic IFN-I, we both knocked out (via 
CRISPR/Cas9 in human HNSCC cells) and knocked down (via shRNA in MOC2-E6/E7) 
NLRC3 expression, then stimulated cells with agonists of the IFN-I pathway. These experiments 
revealed that NLRC3 in negatively regulates IFN-I production in cancer cells. In vivo loss of 
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cancer-intrinsic NLRC3 led to reduced tumor burdens and increased infiltrates of TCRb+ and 
TCRgd+ cells. In addition, further experiments utilizing Rag1-deficient and Ifnar1-deficient mice 
confirmed the necessity of host adaptive immune cell responses and host downstream IFNAR1 
signaling towards the effects of cancer-intrinsic NLRC3 loss. 
Recent work has suggested that chronic inflammation in obese patients leads to better 
response rates to checkpoint therapies (136). However, it has also been reported in cancer models 
that components of adipose tissue, such as leptin, contribute to increased PD-1 expression and 
dysregulated T-cell activation (137). Thus, from our work analyzing the relationship between the 
innate immune sensor NLRC3 and saturated fatty acids, certain important future directions 
emerge. The first concerns the regulation of NLRC3 itself.  Our findings in chapter 2 suggest that 
saturated fatty acids induce NLRC3 expression, but one limitation to our study is that much is 
still unknown concerning direct regulators of NLRC3 transcription and functional activation. 
Previous reports have indicated that saturated fatty acids are potent drivers of ER stress and 
cellular injury, which subsequently promotes immunosuppressive myeloid cell expansion in the 
tumor microenvironment (138, 139), as well as activation of the pathogen recognition receptor 
NLRP3 (140). Potential in vivo carbon tracing experiments utilizing [13C]-glucose, which have 
been used to uncover differential use of glucose in T-cells in vivo (141), could also further 
uncover if dysregulated metabolites of glycolysis interact with NLRC3 machinery to enhance its 
activity. 
It has been recently reported that NLRC3-mediated sequestration of STING is reversed 
by DNA binding to the leucine-rich repeat domain of NLRC3 (114). It is a possibility that 
saturated fatty acids may directly interact on NLRC3 sensing domains, or through an ER stress-
mediated molecular reprogramming. We additionally acknowledge that one technical limitation 
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to this study is the lack of a functional NLRC3 antibody. However, qPCR analysis of NLRC3, in 
addition to downstream induction of IFN-related gene signatures, and protein analysis of the 
STING pathway intermediates confirm cancer-intrinsic NLRC3 loss.  Another interesting 
question pertains to the effects of weight loss on HNSCC tumor burden, and whether transient 
cancer cell-saturated fatty acid interaction may contribute to a fluctuating IFN-I and anti-tumor 
immune response. Lastly, a question emerges concerning host-intrinsic NLRC3 as a potentially 
targetable protein to enhance anti-tumor immunity. By uncovering how IFN-I signaling expands 
or retracts effectors in the tumor microenvironment, this mechanism can be used to enhance 
current combinatorial treatment modalities. 
Objectives, Major Findings, and Implications from Chapter 3 
Much has been previously addressed concerning the immune priming effects of IFN-I 
production on skewing anti-tumor immune responses towards effector phenotypes. However, not 
much has been understood concerning the mechanisms of downstream cancer-intrinsic IFNAR1 
engagement and signaling in tumor modulation. Thus, in this chapter, our objective was to better 
characterize the mechanisms driving cancer resistance to STING-inducing priming therapies, we 
dissected the differences between IFNAR1 signaling in cancer cells from the IFN-I signaling in 
immune cells. From this work, we uncovered that downstream IFNAR1 signaling activation in 
cancer cells, via the surrogate “metagene” MX1, is associated with poor clinical outcomes. In 
addition, by blocking IFNAR1 signaling in the tumor cells, we noted expansions of stem-like 
effector T-cells, restriction of myeloid cell-derived suppressor cells (MDSCs), and global 
reduction in tumor burden. In our stemness assay, we examined the proliferative properties of the 
MOC2-E6/E7 cell line in vitro. However, a more comprehensive approach for future work would 
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be to assess the cancer stem cell compartment from our shIfnar1-MOC2-E6/E7 in vivo tumor 
models. 
We postulate that the future development of robust IFN-I-inducing formulations is 
important to rapidly control tumors through myeloid reprogramming while avoiding prolonged 
stimulation of HNSCC cells, which triggers an adaptive mechanism promoting resistance to 
innate immune priming strategies. One possibility by which this resistance mechanism occurs is 
through the protein complex NF-kB. NF-kB activation is known to be critical for IFN-I 
induction. It is frequently activated in HNSCC (142), and its activation in tumor cells enhances 
HNSCC invasion and resistance to therapy (143-145). Thus, the duration of immune activation 
therapy is also likely shaping the evolution of tumor resistance. Most preclinical models for 
STING1 agonists testing were based on relatively acute administration into implantable 
subcutaneous tumor models. Chronic STING1 stimulation likely results in sustained NF-kB 
activation in tumor cells. This pathway encourages transcriptional programs associated with 
stemness that is associated with a more tolerogenic local immune niche.   
To enhance the therapeutic effectiveness and avoid chronic STING1 stimulation, several 
robust delivery vehicles have been engineered for STING1 agonists. Controlled release of 
STING1 agonists using a peptide hydrogel significantly extends the survival of tumor-bearing 
mice compared to treatment with free STING1 agonists treatment alone (23). When STING1 
agonists are delivered using nanoparticles in combination with ICB, tumor-specific CD8+ T-cells 
are significantly expanded (16). Similarly, two other delivery systems including endosomolytic 
polymersomes nanoparticles and biodegradable polymer acetylated dextran microparticles also 
enhance the efficacy of STING1 (146, 147). Nanoparticles and microparticles are preferably 
taken up by myeloid cells and protect cargo from rapid degradation. Due to the unfavorable 
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pharmacokinetics property of free cGAMP, the integration of these delivery systems is a highly 
promising strategy to enhance myeloid response and avoid chronic stimulation of the IFNAR1 
signaling in cancer cells. Finally, we speculate that targeting cancer stemness could be a viable 
treatment option, should targeted STING1 therapies produce downstream cancer-specific 
IFNAR1 activation. For one, the anti-CD44v6 monoclonal antibody bivatuzumab has been 
administered in phase I clinical trials for recurrent/metastatic HNSCC (148). We hypothesize 
that combinatorial therapies such as these will alleviate detrimental off-target effects and 
improve tumor regression outcomes. 
Final Thoughts 
The research outlined in this dissertation expands our understanding of the pleiotropic, 
differential mechanisms by which STING-mediated IFN-I production and signaling enacts both 
immune cell effector cell expansion as well as immune evasion by the induction of cancer stem 
cells. We highlight a novel strategy by which obesity constrains anti-tumor immunity, by the 
promotion of an innate immune sensor. It is certainly a goal of future work to further reveal the 
nature of NLRC3 regulation and sensing. More accurate NLRC3 antibodies, as well as 
characterization of Nlrc3-deficient tumors within Nlrc3-/- hosts will expand our understanding of 
interaction between host- and tumor-intrinsic IFN-I regulatory mechanisms. Extensive immune 
cell profiling of the myeloid compartment from these tumors would additionally broaden our 
knowledge of cellular-mediated mechanisms aiding immunosuppression. Thus, we postulate that 
future investigations examining such interactions will provide greater context towards our 
understanding of sensing-mediated immunosuppression. We additionally speculate that future 
pharmacologic agents will deliver targeted STING1 agonists to activate and expand cytolytic 
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